[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fWAOAgUHoALVupZOYiKBEzBSMfHFcsi8hk36kJo5CFco":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"University Hospital Tuebingen",[4],483,false,92,30,143193,39,326,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Obesity",16,{"name":18,"count":19},"Insulin Resistance",13,{"name":21,"count":22},"Rare Diseases",9,{"name":24,"count":25},"Major Depressive Disorder",8,{"name":27,"count":25},"Depression",{"name":29,"count":30},"COVID-19",7,{"name":32,"count":33},"Malignant Melanoma",6,{"name":35,"count":33},"Genetic Predisposition",[37,42,47,52,56,61,66,71,76,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06290557","First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133","2025-07-01","HY_133",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05871593","CIRculating Cell-free nUcLeic Acids in Cancer Therapy Monitoring -01","2025-10","Molecular genetic diagnostic",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04046796","Genetic Causes of Discrepant Clinic in Monogenic Twins","2025-12","NGS Diagnostic",{"nctId":53,"briefTitle":54,"date":50,"intervention":55},"NCT05646550","Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer","CC-1",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06060184","Initiative for Clinical Long-read Sequencing","2025-12-01","Next-Generation Sequencing",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT04104607","The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma","2025-12-31","CC-1, PSMAxCD3",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06410599","Pharmacologic Treatment Augmentation in Chronic Depression","2026-05","Ketamine",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06252584","Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients","2026-05-02","Vaccines, Peptide",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT05441410","Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP\u002F ChAd63 ME-TRAP in Adults","2026-06-30","Pyronaridine Tetraphosphate, Artesunate Drug Combination",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT04760522","Genome-based Management of Patients in Precision Medicine (Ge-Med) Towards a Genomic Health Program","2026-07","WGS Diagnostic: Blood take for genetic diagnostic",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,138,164,182,217,237,262,290,308,326,344,362,389,415,433,460,487,505,532,550,578,602,623,647,672,697,719,740,763,789,810,842,863,888,908,936,958,985,1003,1026,1077,1104,1129,1147,1172,1196,1214,1239,1266,1284,1310,1335,1353,1387,1413,1438,1465,1483,1506,1532,1559,1577,1602,1627,1652,1677,1702,1731,1749,1771,1799,1817,1842,1867,1885,1909,1935,1953,1979,1997,2023,2048,2070,2096,2122,2140,2164,2199,2241,2278,2314,2340,2366,2388,2410,2434,2460,2485,2510,2533,2551,2576,2594,2617,2641,2666,2694,2712,2730,2748,2770,2795,2813,2837,2862,2887,2905,2930,2956,2974,2992,3017,3035,3060,3086,3111,3136,3161,3179,3197,3215,3239,3265,3283,3305,3330,3354,3381,3399,3417,3442,3466,3484,3502,3520,3544,3568,3586,3611,3635,3659,3683,3708,3735,3753,3771,3789,3813,3864,3913,3941,3967,4003,4030,4052,4085,4111,4129,4147,4169,4193,4217,4243,4261,4285,4309,4331,4356,4380,4403,4429,4453,4476,4501,4519,4537,4555,4573,4598,4616,4640,4661,4685,4710,4735,4761],{"intervention":95,"totalTrials":96,"cells":97},"Dapagliflozin",2,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":136},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":135,"soonestReadout":114},[109,123],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":122},"NCT06054035","SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes","RECRUITING",[91],"2027-06-30","2027-09-30","2023-10-26",170,[119,120,121],"Type2diabetes","PreDiabetes","Renal Failure",[95],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":100,"conditions":131,"interventions":133},"NCT03423355","Dapagliflozin Effect on Erythropoiesis and Physical Fitness","WITHDRAWN",[91],"2023-03","2023-12","2021-09",[132],"Type 2 Diabetes Mellitus (T2DM)",[95,134],"Hydrochlorothiazide 25 mg",1,{"trials":137,"activeCount":100},[],{"intervention":139,"totalTrials":135,"cells":140},"LECIG",{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":160,"NA":162},{"trials":142,"activeCount":100},[],{"trials":144,"activeCount":100},[],{"trials":146,"activeCount":100},[],{"trials":148,"activeCount":135,"soonestReadout":153},[149],{"nctId":150,"briefTitle":151,"status":112,"phases":152,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":158},"NCT07151378","Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease",[90],"2030-09-22","2025-10-27",150,[157],"PARKINSON DISEASE (Disorder)",[139,159],"Best oral medication",{"trials":161,"activeCount":100},[],{"trials":163,"activeCount":100},[],{"intervention":159,"totalTrials":135,"cells":165},{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":172,"PHASE4":178,"NA":180},{"trials":167,"activeCount":100},[],{"trials":169,"activeCount":100},[],{"trials":171,"activeCount":100},[],{"trials":173,"activeCount":135,"soonestReadout":153},[174],{"nctId":150,"briefTitle":151,"status":112,"phases":175,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":176,"interventions":177},[90],[157],[139,159],{"trials":179,"activeCount":100},[],{"trials":181,"activeCount":100},[],{"intervention":183,"totalTrials":96,"cells":184},"PfSPZ Challenge",{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":200,"PHASE3":211,"PHASE4":213,"NA":215},{"trials":186,"activeCount":100},[],{"trials":188,"activeCount":100},[189],{"nctId":190,"briefTitle":191,"status":192,"phases":193,"primaryCompletion":194,"completion":194,"start":195,"enrollment":9,"conditions":196,"interventions":198},"NCT02858817","Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A\u002FP Chemoprophylaxis","COMPLETED",[88],"2017-11-16","2016-11-28",[197],"Malaria",[199,183],"atovaquone\u002Fproguanil 250mg\u002F100mg",{"trials":201,"activeCount":135,"soonestReadout":79},[202],{"nctId":77,"briefTitle":78,"status":203,"phases":204,"primaryCompletion":79,"completion":79,"start":205,"enrollment":9,"conditions":206,"interventions":207},"NOT_YET_RECRUITING",[88,89],"2025-06-01",[197],[80,183,208,209,210],"MVA ME-TRAP","ChAd63 ME-TRAP","Sodium chloride (NaCl) 0.9%",{"trials":212,"activeCount":100},[],{"trials":214,"activeCount":100},[],{"trials":216,"activeCount":100},[],{"intervention":70,"totalTrials":135,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":231,"PHASE4":233,"NA":235},{"trials":220,"activeCount":100},[],{"trials":222,"activeCount":100},[],{"trials":224,"activeCount":135,"soonestReadout":69},[225],{"nctId":67,"briefTitle":68,"status":112,"phases":226,"primaryCompletion":69,"completion":84,"start":227,"enrollment":228,"conditions":229,"interventions":230},[89],"2024-04-29",60,[24],[70],{"trials":232,"activeCount":100},[],{"trials":234,"activeCount":100},[],{"trials":236,"activeCount":100},[],{"intervention":238,"totalTrials":135,"cells":239},"CD318-CAR-T cells",{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":256,"PHASE4":258,"NA":260},{"trials":241,"activeCount":100},[],{"trials":243,"activeCount":100},[],{"trials":245,"activeCount":135,"soonestReadout":250},[246],{"nctId":247,"briefTitle":248,"status":203,"phases":249,"primaryCompletion":250,"completion":250,"start":84,"enrollment":251,"conditions":252,"interventions":255},"NCT07153289","CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)",[88,89],"2028-12",38,[253,254],"Carcinoma, Pancreatic Ductal","Pancreatic Neoplasms",[238],{"trials":257,"activeCount":100},[],{"trials":259,"activeCount":100},[],{"trials":261,"activeCount":100},[],{"intervention":263,"totalTrials":135,"cells":264},"RIC regimen",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":284,"PHASE4":286,"NA":288},{"trials":266,"activeCount":100},[],{"trials":268,"activeCount":100},[],{"trials":270,"activeCount":135,"soonestReadout":275},[271],{"nctId":272,"briefTitle":273,"status":203,"phases":274,"primaryCompletion":275,"completion":276,"start":277,"enrollment":278,"conditions":279,"interventions":283},"NCT07214064","Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation",[89],"2027-08","2027-12","2026-01",27,[280,281,282],"AML (Acute Myeloid Leukemia)","MDS\u002FAML","MDS (Myelodysplastic Syndrome)",[263],{"trials":285,"activeCount":100},[],{"trials":287,"activeCount":100},[],{"trials":289,"activeCount":100},[],{"intervention":80,"totalTrials":135,"cells":291},{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":302,"PHASE4":304,"NA":306},{"trials":293,"activeCount":100},[],{"trials":295,"activeCount":100},[],{"trials":297,"activeCount":135,"soonestReadout":79},[298],{"nctId":77,"briefTitle":78,"status":203,"phases":299,"primaryCompletion":79,"completion":79,"start":205,"enrollment":9,"conditions":300,"interventions":301},[88,89],[197],[80,183,208,209,210],{"trials":303,"activeCount":100},[],{"trials":305,"activeCount":100},[],{"trials":307,"activeCount":100},[],{"intervention":208,"totalTrials":135,"cells":309},{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":320,"PHASE4":322,"NA":324},{"trials":311,"activeCount":100},[],{"trials":313,"activeCount":100},[],{"trials":315,"activeCount":135,"soonestReadout":79},[316],{"nctId":77,"briefTitle":78,"status":203,"phases":317,"primaryCompletion":79,"completion":79,"start":205,"enrollment":9,"conditions":318,"interventions":319},[88,89],[197],[80,183,208,209,210],{"trials":321,"activeCount":100},[],{"trials":323,"activeCount":100},[],{"trials":325,"activeCount":100},[],{"intervention":209,"totalTrials":135,"cells":327},{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":338,"PHASE4":340,"NA":342},{"trials":329,"activeCount":100},[],{"trials":331,"activeCount":100},[],{"trials":333,"activeCount":135,"soonestReadout":79},[334],{"nctId":77,"briefTitle":78,"status":203,"phases":335,"primaryCompletion":79,"completion":79,"start":205,"enrollment":9,"conditions":336,"interventions":337},[88,89],[197],[80,183,208,209,210],{"trials":339,"activeCount":100},[],{"trials":341,"activeCount":100},[],{"trials":343,"activeCount":100},[],{"intervention":210,"totalTrials":135,"cells":345},{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":350,"PHASE3":356,"PHASE4":358,"NA":360},{"trials":347,"activeCount":100},[],{"trials":349,"activeCount":100},[],{"trials":351,"activeCount":135,"soonestReadout":79},[352],{"nctId":77,"briefTitle":78,"status":203,"phases":353,"primaryCompletion":79,"completion":79,"start":205,"enrollment":9,"conditions":354,"interventions":355},[88,89],[197],[80,183,208,209,210],{"trials":357,"activeCount":100},[],{"trials":359,"activeCount":100},[],{"trials":361,"activeCount":100},[],{"intervention":363,"totalTrials":135,"cells":364},"Prednisolone",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":383,"PHASE4":385,"NA":387},{"trials":366,"activeCount":100},[],{"trials":368,"activeCount":100},[],{"trials":370,"activeCount":135,"soonestReadout":375},[371],{"nctId":372,"briefTitle":373,"status":112,"phases":374,"primaryCompletion":375,"completion":375,"start":376,"enrollment":377,"conditions":378,"interventions":382},"NCT06953791","Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Patients",[89],"2028-02-01","2026-02-01",52,[379,380,381],"Crohn Disease","Nutrition Assessment","Diet Therapy",[363],{"trials":384,"activeCount":100},[],{"trials":386,"activeCount":100},[],{"trials":388,"activeCount":100},[],{"intervention":390,"totalTrials":135,"cells":391},"Prasinezumab",{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":409,"PHASE4":411,"NA":413},{"trials":393,"activeCount":100},[],{"trials":395,"activeCount":100},[],{"trials":397,"activeCount":135,"soonestReadout":402},[398],{"nctId":399,"briefTitle":400,"status":203,"phases":401,"primaryCompletion":402,"completion":403,"start":50,"enrollment":404,"conditions":405,"interventions":407},"NCT07055087","Prevent Cognitive Decline in GBA-associated Parkinson's Disease",[89],"2030-12","2031-05",120,[406],"Parkinson's Disease",[390,408],"Sodium Chloride",{"trials":410,"activeCount":100},[],{"trials":412,"activeCount":100},[],{"trials":414,"activeCount":100},[],{"intervention":408,"totalTrials":135,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":427,"PHASE4":429,"NA":431},{"trials":418,"activeCount":100},[],{"trials":420,"activeCount":100},[],{"trials":422,"activeCount":135,"soonestReadout":402},[423],{"nctId":399,"briefTitle":400,"status":203,"phases":424,"primaryCompletion":402,"completion":403,"start":50,"enrollment":404,"conditions":425,"interventions":426},[89],[406],[390,408],{"trials":428,"activeCount":100},[],{"trials":430,"activeCount":100},[],{"trials":432,"activeCount":100},[],{"intervention":434,"totalTrials":135,"cells":435},"Peptide vaccine IPX",{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":454,"PHASE4":456,"NA":458},{"trials":437,"activeCount":100},[],{"trials":439,"activeCount":100},[],{"trials":441,"activeCount":135,"soonestReadout":446},[442],{"nctId":443,"briefTitle":444,"status":112,"phases":445,"primaryCompletion":446,"completion":447,"start":448,"enrollment":9,"conditions":449,"interventions":453},"NCT06094101","Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)",[88,89],"2027-06","2027-09","2023-09-19",[450,451,452],"Ewing Sarcoma","Rhabdomyosarcoma","Synovial Sarcoma",[434],{"trials":455,"activeCount":100},[],{"trials":457,"activeCount":100},[],{"trials":459,"activeCount":100},[],{"intervention":461,"totalTrials":135,"cells":462},"Decitabine",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":481,"PHASE4":483,"NA":485},{"trials":464,"activeCount":100},[],{"trials":466,"activeCount":100},[],{"trials":468,"activeCount":135,"soonestReadout":473},[469],{"nctId":470,"briefTitle":471,"status":112,"phases":472,"primaryCompletion":473,"completion":474,"start":475,"enrollment":278,"conditions":476,"interventions":479},"NCT06156579","Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed\u002FRefractory AML",[89],"2026-09-01","2027-03","2023-11-04",[477,478],"AML","MDS",[461,480],"Venetoclax",{"trials":482,"activeCount":100},[],{"trials":484,"activeCount":100},[],{"trials":486,"activeCount":100},[],{"intervention":480,"totalTrials":135,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":499,"PHASE4":501,"NA":503},{"trials":490,"activeCount":100},[],{"trials":492,"activeCount":100},[],{"trials":494,"activeCount":135,"soonestReadout":473},[495],{"nctId":470,"briefTitle":471,"status":112,"phases":496,"primaryCompletion":473,"completion":474,"start":475,"enrollment":278,"conditions":497,"interventions":498},[89],[477,478],[461,480],{"trials":500,"activeCount":100},[],{"trials":502,"activeCount":100},[],{"trials":504,"activeCount":100},[],{"intervention":506,"totalTrials":135,"cells":507},"Belimumab 200 MG\u002FML [Benlysta]",{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":526,"PHASE4":528,"NA":530},{"trials":509,"activeCount":100},[],{"trials":511,"activeCount":100},[],{"trials":513,"activeCount":135,"soonestReadout":519},[514],{"nctId":515,"briefTitle":516,"status":517,"phases":518,"primaryCompletion":519,"completion":520,"start":521,"enrollment":404,"conditions":522,"interventions":524},"NCT05069051","Belimumab in Patients with Chronic Lymphocytic Leukemia","ACTIVE_NOT_RECRUITING",[89],"2026-07-15","2027-07-14","2022-01-19",[523],"Chronic Lymphoid Leukemia in Relapse",[506,525],"standard of care",{"trials":527,"activeCount":100},[],{"trials":529,"activeCount":100},[],{"trials":531,"activeCount":100},[],{"intervention":525,"totalTrials":135,"cells":533},{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":544,"PHASE4":546,"NA":548},{"trials":535,"activeCount":100},[],{"trials":537,"activeCount":100},[],{"trials":539,"activeCount":135,"soonestReadout":519},[540],{"nctId":515,"briefTitle":516,"status":517,"phases":541,"primaryCompletion":519,"completion":520,"start":521,"enrollment":404,"conditions":542,"interventions":543},[89],[523],[506,525],{"trials":545,"activeCount":100},[],{"trials":547,"activeCount":100},[],{"trials":549,"activeCount":100},[],{"intervention":551,"totalTrials":135,"cells":552},"Tafasitamab",{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":572,"PHASE4":574,"NA":576},{"trials":554,"activeCount":100},[],{"trials":556,"activeCount":100},[],{"trials":558,"activeCount":135,"soonestReadout":563},[559],{"nctId":560,"briefTitle":561,"status":112,"phases":562,"primaryCompletion":563,"completion":564,"start":565,"enrollment":566,"conditions":567,"interventions":571},"NCT05366218","Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia",[88,89],"2028-07","2029-02","2023-03-08",20,[568,569,570],"ALL, Childhood B-Cell","Acute Lymphoid Leukemia Relapse","Acute Lymphocytic Leukemia Refractory",[551],{"trials":573,"activeCount":100},[],{"trials":575,"activeCount":100},[],{"trials":577,"activeCount":100},[],{"intervention":579,"totalTrials":135,"cells":580},"CD45RA depleted donor lymphocyte",{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":596,"PHASE4":598,"NA":600},{"trials":582,"activeCount":100},[],{"trials":584,"activeCount":100},[],{"trials":586,"activeCount":135,"soonestReadout":591},[587],{"nctId":588,"briefTitle":589,"status":112,"phases":590,"primaryCompletion":591,"completion":250,"start":592,"enrollment":228,"conditions":593,"interventions":595},"NCT05943067","CD45RA Depleted DLI After TCRα\u002Fβ Depleted Haploidentical HCT",[88,89],"2028-01","2023-04-27",[594],"Hematologic Malignancy",[579],{"trials":597,"activeCount":100},[],{"trials":599,"activeCount":100},[],{"trials":601,"activeCount":100},[],{"intervention":65,"totalTrials":135,"cells":603},{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":615,"PHASE3":617,"PHASE4":619,"NA":621},{"trials":605,"activeCount":100},[],{"trials":607,"activeCount":135,"soonestReadout":64},[608],{"nctId":62,"briefTitle":63,"status":112,"phases":609,"primaryCompletion":64,"completion":64,"start":610,"enrollment":611,"conditions":612,"interventions":614},[88],"2019-11-15",86,[613],"Castration-Resistant Prostatic Cancer",[65],{"trials":616,"activeCount":100},[],{"trials":618,"activeCount":100},[],{"trials":620,"activeCount":100},[],{"trials":622,"activeCount":100},[],{"intervention":624,"totalTrials":135,"cells":625},"Vaccination of Fusion-VAC-XS15",{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":639,"PHASE3":641,"PHASE4":643,"NA":645},{"trials":627,"activeCount":100},[],{"trials":629,"activeCount":135,"soonestReadout":634},[630],{"nctId":631,"briefTitle":632,"status":112,"phases":633,"primaryCompletion":634,"completion":634,"start":635,"enrollment":566,"conditions":636,"interventions":638},"NCT06789198","Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA",[88],"2028-11","2025-07-08",[637],"Fibrolamellar Hepatocellular Carcinoma (FLC)",[624],{"trials":640,"activeCount":100},[],{"trials":642,"activeCount":100},[],{"trials":644,"activeCount":100},[],{"trials":646,"activeCount":100},[],{"intervention":648,"totalTrials":135,"cells":649},"Nivolumab [Opdivo]",{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":664,"PHASE3":666,"PHASE4":668,"NA":670},{"trials":651,"activeCount":100},[],{"trials":653,"activeCount":135,"soonestReadout":658},[654],{"nctId":655,"briefTitle":656,"status":112,"phases":657,"primaryCompletion":658,"completion":115,"start":659,"enrollment":660,"conditions":661,"interventions":663},"NCT05112549","Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1\u002F NOA 26)",[88],"2026-12-31","2021-10-12",46,[662],"Leptomeningeal Disease",[648],{"trials":665,"activeCount":100},[],{"trials":667,"activeCount":100},[],{"trials":669,"activeCount":100},[],{"trials":671,"activeCount":100},[],{"intervention":673,"totalTrials":135,"cells":674},"Fusion-VAC-XS15",{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":689,"PHASE3":691,"PHASE4":693,"NA":695},{"trials":676,"activeCount":100},[],{"trials":678,"activeCount":135,"soonestReadout":683},[679],{"nctId":680,"briefTitle":681,"status":112,"phases":682,"primaryCompletion":683,"completion":684,"start":685,"enrollment":566,"conditions":686,"interventions":688},"NCT05937295","FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition",[88],"2026-09","2027-01","2023-09-26",[687],"Fibrolamellar Hepatocellular Carcinoma",[673],{"trials":690,"activeCount":100},[],{"trials":692,"activeCount":100},[],{"trials":694,"activeCount":100},[],{"trials":696,"activeCount":100},[],{"intervention":55,"totalTrials":135,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":711,"PHASE3":713,"PHASE4":715,"NA":717},{"trials":700,"activeCount":100},[],{"trials":702,"activeCount":135,"soonestReadout":50},[703],{"nctId":53,"briefTitle":54,"status":112,"phases":704,"primaryCompletion":50,"completion":705,"start":706,"enrollment":707,"conditions":708,"interventions":710},[88],"2026-12","2022-11-11",56,[709],"Prostate Cancer Recurrent",[55],{"trials":712,"activeCount":100},[],{"trials":714,"activeCount":100},[],{"trials":716,"activeCount":100},[],{"trials":718,"activeCount":100},[],{"intervention":41,"totalTrials":135,"cells":720},{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":732,"PHASE3":734,"PHASE4":736,"NA":738},{"trials":722,"activeCount":100},[],{"trials":724,"activeCount":135,"soonestReadout":40},[725],{"nctId":38,"briefTitle":39,"status":112,"phases":726,"primaryCompletion":40,"completion":727,"start":728,"enrollment":377,"conditions":729,"interventions":731},[88],"2026-07-01","2024-07-10",[730],"Staphylococcus Aureus",[41],{"trials":733,"activeCount":100},[],{"trials":735,"activeCount":100},[],{"trials":737,"activeCount":100},[],{"trials":739,"activeCount":100},[],{"intervention":741,"totalTrials":135,"cells":742},"Prime-2-CoV_Beta",{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":755,"PHASE3":757,"PHASE4":759,"NA":761},{"trials":744,"activeCount":100},[],{"trials":746,"activeCount":135,"soonestReadout":658},[747],{"nctId":748,"briefTitle":749,"status":112,"phases":750,"primaryCompletion":658,"completion":658,"start":751,"enrollment":752,"conditions":753,"interventions":754},"NCT05389319","A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults",[88],"2022-06-24",96,[29],[741],{"trials":756,"activeCount":100},[],{"trials":758,"activeCount":100},[],{"trials":760,"activeCount":100},[],{"trials":762,"activeCount":100},[],{"intervention":764,"totalTrials":135,"cells":765},"CAR-T cells targeting CD19 and CD22",{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":781,"PHASE3":783,"PHASE4":785,"NA":787},{"trials":767,"activeCount":100},[],{"trials":769,"activeCount":135,"soonestReadout":474},[770],{"nctId":771,"briefTitle":772,"status":112,"phases":773,"primaryCompletion":474,"completion":446,"start":774,"enrollment":775,"conditions":776,"interventions":780},"NCT07108868","A Phase I Dose Finding Study of MB-CART2219.1",[88],"2025-06-23",36,[777,778,779],"Lymphoma","CLL","Acute Lymphoblastic Leukemia, Pediatric",[764],{"trials":782,"activeCount":100},[],{"trials":784,"activeCount":100},[],{"trials":786,"activeCount":100},[],{"trials":788,"activeCount":100},[],{"intervention":75,"totalTrials":135,"cells":790},{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":802,"PHASE3":804,"PHASE4":806,"NA":808},{"trials":792,"activeCount":100},[],{"trials":794,"activeCount":135,"soonestReadout":74},[795],{"nctId":72,"briefTitle":73,"status":203,"phases":796,"primaryCompletion":74,"completion":797,"start":798,"enrollment":566,"conditions":799,"interventions":801},[88],"2026-11-02","2024-05-02",[800],"Acute Myeloid Leukemia, Adult",[75],{"trials":803,"activeCount":100},[],{"trials":805,"activeCount":100},[],{"trials":807,"activeCount":100},[],{"trials":809,"activeCount":100},[],{"intervention":51,"totalTrials":96,"cells":811},{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":818,"PHASE4":820,"NA":822},{"trials":813,"activeCount":100},[],{"trials":815,"activeCount":100},[],{"trials":817,"activeCount":100},[],{"trials":819,"activeCount":100},[],{"trials":821,"activeCount":100},[],{"trials":823,"activeCount":135,"soonestReadout":50},[824,831],{"nctId":48,"briefTitle":49,"status":112,"phases":825,"primaryCompletion":50,"completion":276,"start":826,"enrollment":827,"conditions":828,"interventions":830},[],"2019-12-01",50,[21,829],"Genetic Predisposition to Disease",[51],{"nctId":832,"briefTitle":833,"status":834,"phases":835,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":841},"NCT03491280","Diagnostic Research in Patients With Rare Diseases - Solving the Unsolved Rare Diseases","UNKNOWN",[],"2023-04","2025-04","2018-05-01",5500,[21,35],[51],{"intervention":60,"totalTrials":135,"cells":843},{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":848,"PHASE3":850,"PHASE4":852,"NA":854},{"trials":845,"activeCount":100},[],{"trials":847,"activeCount":100},[],{"trials":849,"activeCount":100},[],{"trials":851,"activeCount":100},[],{"trials":853,"activeCount":100},[],{"trials":855,"activeCount":135,"soonestReadout":59},[856],{"nctId":57,"briefTitle":58,"status":203,"phases":857,"primaryCompletion":59,"completion":858,"start":859,"enrollment":860,"conditions":861,"interventions":862},[92],"2026-12-01","2023-12-01",500,[35],[60],{"intervention":864,"totalTrials":135,"cells":865},"Retrospective data analysis",{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":870,"PHASE3":872,"PHASE4":874,"NA":876},{"trials":867,"activeCount":100},[],{"trials":869,"activeCount":100},[],{"trials":871,"activeCount":100},[],{"trials":873,"activeCount":100},[],{"trials":875,"activeCount":100},[],{"trials":877,"activeCount":135,"soonestReadout":882},[878],{"nctId":879,"briefTitle":880,"status":112,"phases":881,"primaryCompletion":882,"completion":883,"start":884,"enrollment":885,"conditions":886,"interventions":887},"NCT04731857","Diagnostic Value of Exome\u002F Genome Sequencing, Conventional Methods in Rare Diseases and Familial Tumor Syndromes",[],"2030-02","2031-02","2021-02-18",12000,[21,35],[864],{"intervention":85,"totalTrials":135,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":898,"NA":900},{"trials":891,"activeCount":100},[],{"trials":893,"activeCount":100},[],{"trials":895,"activeCount":100},[],{"trials":897,"activeCount":100},[],{"trials":899,"activeCount":100},[],{"trials":901,"activeCount":135,"soonestReadout":84},[902],{"nctId":82,"briefTitle":83,"status":112,"phases":903,"primaryCompletion":84,"completion":904,"start":905,"enrollment":885,"conditions":906,"interventions":907},[92],"2027-07","2021-06-01",[21,829],[85],{"intervention":909,"totalTrials":135,"cells":910},"Biologic Agent",{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":917,"PHASE4":919,"NA":921},{"trials":912,"activeCount":100},[],{"trials":914,"activeCount":100},[],{"trials":916,"activeCount":100},[],{"trials":918,"activeCount":100},[],{"trials":920,"activeCount":100},[],{"trials":922,"activeCount":135,"soonestReadout":927},[923],{"nctId":924,"briefTitle":925,"status":112,"phases":926,"primaryCompletion":927,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":935},"NCT07132333","Molecular Inflammation Board at the Center for Personalized Medicine",[],"2032-11","2022-11-16",3000,[931,932,933,934],"Psoriasis (PsO)","Psoriasis Arthritis","Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)","Spondylarthropathies",[909],{"intervention":46,"totalTrials":135,"cells":937},{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":944,"PHASE4":946,"NA":948},{"trials":939,"activeCount":100},[],{"trials":941,"activeCount":100},[],{"trials":943,"activeCount":100},[],{"trials":945,"activeCount":100},[],{"trials":947,"activeCount":100},[],{"trials":949,"activeCount":135,"soonestReadout":45},[950],{"nctId":43,"briefTitle":44,"status":203,"phases":951,"primaryCompletion":45,"completion":952,"start":953,"enrollment":954,"conditions":955,"interventions":957},[92],"2026-10","2023-10",200,[956],"Next-Generation-Sequencing",[46],{"intervention":959,"totalTrials":135,"cells":960},"Chemotherapy with 5-fluorouracil",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":967,"PHASE4":969,"NA":971},{"trials":962,"activeCount":100},[],{"trials":964,"activeCount":100},[],{"trials":966,"activeCount":100},[],{"trials":968,"activeCount":100},[],{"trials":970,"activeCount":100},[],{"trials":972,"activeCount":135,"soonestReadout":977},[973],{"nctId":974,"briefTitle":975,"status":112,"phases":976,"primaryCompletion":977,"completion":978,"start":979,"enrollment":980,"conditions":981,"interventions":983},"NCT06831981","Hyperthermia With Chemoradiotherapy in Rectal Cancer",[92],"2036-06-01","2037-03-01","2024-09-11",264,[982],"Rectal Cancer",[959,984],"Consolidation chemotherapy with FOLFOX",{"intervention":984,"totalTrials":135,"cells":986},{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":993,"PHASE4":995,"NA":997},{"trials":988,"activeCount":100},[],{"trials":990,"activeCount":100},[],{"trials":992,"activeCount":100},[],{"trials":994,"activeCount":100},[],{"trials":996,"activeCount":100},[],{"trials":998,"activeCount":135,"soonestReadout":977},[999],{"nctId":974,"briefTitle":975,"status":112,"phases":1000,"primaryCompletion":977,"completion":978,"start":979,"enrollment":980,"conditions":1001,"interventions":1002},[92],[982],[959,984],{"intervention":1004,"totalTrials":135,"cells":1005},"SSRI treatment",{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1012,"PHASE4":1014,"NA":1016},{"trials":1007,"activeCount":100},[],{"trials":1009,"activeCount":100},[],{"trials":1011,"activeCount":100},[],{"trials":1013,"activeCount":100},[],{"trials":1015,"activeCount":100},[],{"trials":1017,"activeCount":135,"soonestReadout":658},[1018],{"nctId":1019,"briefTitle":1020,"status":203,"phases":1021,"primaryCompletion":658,"completion":658,"start":1022,"enrollment":1023,"conditions":1024,"interventions":1025},"NCT06545474","Effects of rTMS Compared to SSRI as Early Treatment of Depression (Early-TMS)",[92],"2024-09-15",106,[24],[1004],{"intervention":1027,"totalTrials":1028,"cells":1029},"Imiquimod",3,{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1061,"PHASE4":1063,"NA":1075},{"trials":1031,"activeCount":100},[],{"trials":1033,"activeCount":100},[],{"trials":1035,"activeCount":100},[1036,1050],{"nctId":1037,"briefTitle":1038,"status":834,"phases":1039,"primaryCompletion":1040,"completion":1040,"start":1041,"enrollment":775,"conditions":1042,"interventions":1044},"NCT02452307","Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy",[88,89],"2017-10","2004-04",[1043],"Recurrent Prostate Cancer",[1045,1046,1047,1027,1048,1049],"Peptide vaccine","Montanide ISA-51","Granulocyte macrophage colony stimulating factor","mRNA","Protamin",{"nctId":1051,"briefTitle":1052,"status":192,"phases":1053,"primaryCompletion":1054,"completion":1055,"start":1056,"enrollment":707,"conditions":1057,"interventions":1059},"NCT02802943","iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL",[89],"2022-09-30","2022-11-18","2016-10-05",[1058],"Leukemia, Chronic Lymphatic",[1060,1027],"Peptide Vaccine",{"trials":1062,"activeCount":100},[],{"trials":1064,"activeCount":100},[1065],{"nctId":1066,"briefTitle":1067,"status":192,"phases":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1074},"NCT00204555","Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma",[91],"2005-09","2002-01",100,[1073],"Carcinoma, Basal Cell",[1027],{"trials":1076,"activeCount":100},[],{"intervention":1078,"totalTrials":135,"cells":1079},"Detemir",{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1084,"PHASE3":1086,"PHASE4":1088,"NA":1102},{"trials":1081,"activeCount":100},[],{"trials":1083,"activeCount":100},[],{"trials":1085,"activeCount":100},[],{"trials":1087,"activeCount":100},[],{"trials":1089,"activeCount":100},[1090],{"nctId":1091,"briefTitle":1092,"status":1093,"phases":1094,"completion":1095,"start":1096,"enrollment":1097,"conditions":1098,"interventions":1101},"NCT00490893","Hypoglycemia Counterregulation and Symptom Perception With Insulin Detemir","TERMINATED",[91],"2006-12","2006-03",12,[1099,1100],"Diabetes Mellitus","Hypoglycemia",[1078],{"trials":1103,"activeCount":100},[],{"intervention":1105,"totalTrials":135,"cells":1106},"IGlarLixi",{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1113,"PHASE4":1115,"NA":1127},{"trials":1108,"activeCount":100},[],{"trials":1110,"activeCount":100},[],{"trials":1112,"activeCount":100},[],{"trials":1114,"activeCount":100},[],{"trials":1116,"activeCount":100},[1117],{"nctId":1118,"briefTitle":1119,"status":1093,"phases":1120,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":135,"conditions":1123,"interventions":1125},"NCT03881995","Effects of Insulin Glargine and Lixisenatide on the Brain",[91],"2020-06-29","2019-03-18",[1124],"Diabetes Mellitus, Type 2",[1105,1126],"Insulin Glargine 100 UNT\u002FML",{"trials":1128,"activeCount":100},[],{"intervention":1126,"totalTrials":135,"cells":1130},{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1137,"PHASE4":1139,"NA":1145},{"trials":1132,"activeCount":100},[],{"trials":1134,"activeCount":100},[],{"trials":1136,"activeCount":100},[],{"trials":1138,"activeCount":100},[],{"trials":1140,"activeCount":100},[1141],{"nctId":1118,"briefTitle":1119,"status":1093,"phases":1142,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":135,"conditions":1143,"interventions":1144},[91],[1124],[1105,1126],{"trials":1146,"activeCount":100},[],{"intervention":1148,"totalTrials":135,"cells":1149},"levetiracetam",{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1154,"PHASE3":1156,"PHASE4":1158,"NA":1170},{"trials":1151,"activeCount":100},[],{"trials":1153,"activeCount":100},[],{"trials":1155,"activeCount":100},[],{"trials":1157,"activeCount":100},[],{"trials":1159,"activeCount":100},[1160],{"nctId":1161,"briefTitle":1162,"status":192,"phases":1163,"primaryCompletion":1164,"completion":1164,"start":1165,"enrollment":9,"conditions":1166,"interventions":1169},"NCT00571155","Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery",[91],"2009-08","2007-12",[1167,1168],"Primary Brain Tumor","Epilepsy",[1148],{"trials":1171,"activeCount":100},[],{"intervention":1173,"totalTrials":135,"cells":1174},"Budesonide 2 single doses, Metronidazole multiple-dose",{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1181,"PHASE4":1183,"NA":1194},{"trials":1176,"activeCount":100},[],{"trials":1178,"activeCount":100},[],{"trials":1180,"activeCount":100},[],{"trials":1182,"activeCount":100},[],{"trials":1184,"activeCount":100},[1185],{"nctId":1186,"briefTitle":1187,"status":192,"phases":1188,"completion":1189,"start":1190,"enrollment":1097,"conditions":1191,"interventions":1193},"NCT00338910","Pharmacokinetic Interaction Study Between Budesonide and Metronidazole in Healthy Volunteers",[91],"2006-06","2006-05",[1192],"Healthy",[1173],{"trials":1195,"activeCount":100},[],{"intervention":134,"totalTrials":135,"cells":1197},{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1202,"PHASE3":1204,"PHASE4":1206,"NA":1212},{"trials":1199,"activeCount":100},[],{"trials":1201,"activeCount":100},[],{"trials":1203,"activeCount":100},[],{"trials":1205,"activeCount":100},[],{"trials":1207,"activeCount":100},[1208],{"nctId":124,"briefTitle":125,"status":126,"phases":1209,"primaryCompletion":128,"completion":129,"start":130,"enrollment":100,"conditions":1210,"interventions":1211},[91],[132],[95,134],{"trials":1213,"activeCount":100},[],{"intervention":1215,"totalTrials":135,"cells":1216},"Dapagliflozin 10 mg + Saxagliptin 5 mg",{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1221,"PHASE3":1223,"PHASE4":1225,"NA":1237},{"trials":1218,"activeCount":100},[],{"trials":1220,"activeCount":100},[],{"trials":1222,"activeCount":100},[],{"trials":1224,"activeCount":100},[],{"trials":1226,"activeCount":100},[1227],{"nctId":1228,"briefTitle":1229,"status":1093,"phases":1230,"primaryCompletion":1231,"completion":1231,"start":1232,"enrollment":1233,"conditions":1234,"interventions":1236},"NCT02965443","Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment",[91],"2020-02-03","2018-02-02",4,[1235],"Type 2 Diabetes",[1215],{"trials":1238,"activeCount":100},[],{"intervention":1240,"totalTrials":135,"cells":1241},"LCP-tacrolimus",{"EARLY_PHASE1":1242,"PHASE1":1244,"PHASE2":1246,"PHASE3":1248,"PHASE4":1250,"NA":1264},{"trials":1243,"activeCount":100},[],{"trials":1245,"activeCount":100},[],{"trials":1247,"activeCount":100},[],{"trials":1249,"activeCount":100},[],{"trials":1251,"activeCount":100},[1252],{"nctId":1253,"briefTitle":1254,"status":192,"phases":1255,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1260,"interventions":1262},"NCT05396898","Tacrolimus Formulation and Glucose Metabolism After Kidney Transplantation (TAGLUMET Trial)",[91],"2023-08-04","2023-12-30","2020-12-16",44,[1261],"Posttransplant Diabetes Mellitus",[1240,1263],"twice-daily tacrolimus",{"trials":1265,"activeCount":100},[],{"intervention":1263,"totalTrials":135,"cells":1267},{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1272,"PHASE3":1274,"PHASE4":1276,"NA":1282},{"trials":1269,"activeCount":100},[],{"trials":1271,"activeCount":100},[],{"trials":1273,"activeCount":100},[],{"trials":1275,"activeCount":100},[],{"trials":1277,"activeCount":100},[1278],{"nctId":1253,"briefTitle":1254,"status":192,"phases":1279,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1280,"interventions":1281},[91],[1261],[1240,1263],{"trials":1283,"activeCount":100},[],{"intervention":1285,"totalTrials":135,"cells":1286},"Diclofenac",{"EARLY_PHASE1":1287,"PHASE1":1289,"PHASE2":1291,"PHASE3":1293,"PHASE4":1295,"NA":1308},{"trials":1288,"activeCount":100},[],{"trials":1290,"activeCount":100},[],{"trials":1292,"activeCount":100},[],{"trials":1294,"activeCount":100},[],{"trials":1296,"activeCount":100},[1297],{"nctId":1298,"briefTitle":1299,"status":192,"phases":1300,"primaryCompletion":1301,"completion":1302,"start":1303,"enrollment":1304,"conditions":1305,"interventions":1307},"NCT00204542","Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head",[91],"2009-03","2010-12","2005-06",418,[1306],"Photosensitivity Disorders",[1285,1285],{"trials":1309,"activeCount":100},[],{"intervention":1311,"totalTrials":135,"cells":1312},"Empagliflozin",{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1319,"PHASE4":1321,"NA":1333},{"trials":1314,"activeCount":100},[],{"trials":1316,"activeCount":100},[],{"trials":1318,"activeCount":100},[],{"trials":1320,"activeCount":100},[],{"trials":1322,"activeCount":100},[1323],{"nctId":1324,"briefTitle":1325,"status":126,"phases":1326,"primaryCompletion":1327,"completion":1327,"start":1328,"enrollment":100,"conditions":1329,"interventions":1331},"NCT03437330","Empagliflozin Effect on Glucose Toxicity",[91],"2023-05-03","2021-10-27",[1330],"Type2 Diabetes Mellitus",[1311,1332],"Insulin Glargine",{"trials":1334,"activeCount":100},[],{"intervention":1332,"totalTrials":135,"cells":1336},{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1343,"PHASE4":1345,"NA":1351},{"trials":1338,"activeCount":100},[],{"trials":1340,"activeCount":100},[],{"trials":1342,"activeCount":100},[],{"trials":1344,"activeCount":100},[],{"trials":1346,"activeCount":100},[1347],{"nctId":1324,"briefTitle":1325,"status":126,"phases":1348,"primaryCompletion":1327,"completion":1327,"start":1328,"enrollment":100,"conditions":1349,"interventions":1350},[91],[1330],[1311,1332],{"trials":1352,"activeCount":100},[],{"intervention":1354,"totalTrials":96,"cells":1355},"Hydroxychloroquine",{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1371,"PHASE4":1383,"NA":1385},{"trials":1357,"activeCount":100},[],{"trials":1359,"activeCount":100},[],{"trials":1361,"activeCount":100},[1362],{"nctId":1363,"briefTitle":1364,"status":1093,"phases":1365,"primaryCompletion":1366,"completion":1366,"start":1367,"enrollment":1368,"conditions":1369,"interventions":1370},"NCT04340544","Hydroxychloroquine for the Treatment of Mild COVID-19 Disease",[89],"2020-10-12","2020-04-22",17,[29],[1354],{"trials":1372,"activeCount":100},[1373],{"nctId":1374,"briefTitle":1375,"status":126,"phases":1376,"primaryCompletion":1377,"completion":1378,"start":1379,"enrollment":100,"conditions":1380,"interventions":1382},"NCT04351516","Test and Treat COVID 65plus+",[89,90],"2020-12-31","2021-05-01","2020-04-21",[1381,29],"SARS-CoV 2",[1354],{"trials":1384,"activeCount":100},[],{"trials":1386,"activeCount":100},[],{"intervention":1388,"totalTrials":135,"cells":1389},"Melatonin",{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1396,"PHASE4":1409,"NA":1411},{"trials":1391,"activeCount":100},[],{"trials":1393,"activeCount":100},[],{"trials":1395,"activeCount":100},[],{"trials":1397,"activeCount":100},[1398],{"nctId":1399,"briefTitle":1400,"status":834,"phases":1401,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":1405,"conditions":1406,"interventions":1408},"NCT04122599","Melatonin for Prevention of Post Stroke Delirium",[89,90],"2019-11-01","2019-12-31","2017-07-01",2000,[1407],"Post Stroke Delirium",[1388],{"trials":1410,"activeCount":100},[],{"trials":1412,"activeCount":100},[],{"intervention":1414,"totalTrials":135,"cells":1415},"Dehydroepiandrosterone",{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1422,"PHASE4":1434,"NA":1436},{"trials":1417,"activeCount":100},[],{"trials":1419,"activeCount":100},[],{"trials":1421,"activeCount":100},[],{"trials":1423,"activeCount":100},[1424],{"nctId":1425,"briefTitle":1426,"status":192,"phases":1427,"completion":1428,"start":1429,"enrollment":1430,"conditions":1431,"interventions":1433},"NCT00575341","Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency",[90],"2007-04","2003-10",23,[1432],"Adrenal Insufficiency",[1414],{"trials":1435,"activeCount":100},[],{"trials":1437,"activeCount":100},[],{"intervention":1439,"totalTrials":135,"cells":1440},"Tobramycin Powder",{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1445,"PHASE3":1447,"PHASE4":1461,"NA":1463},{"trials":1442,"activeCount":100},[],{"trials":1444,"activeCount":100},[],{"trials":1446,"activeCount":100},[],{"trials":1448,"activeCount":100},[1449],{"nctId":1450,"briefTitle":1451,"status":192,"phases":1452,"primaryCompletion":1453,"completion":1454,"start":1455,"enrollment":1456,"conditions":1457,"interventions":1459},"NCT03341741","Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients",[90],"2015-12-19","2016-11-25","2014-03-11",26,[1458],"Cystic Fibrosis With Pulmonary Manifestations",[1439,1460],"Colistin",{"trials":1462,"activeCount":100},[],{"trials":1464,"activeCount":100},[],{"intervention":1460,"totalTrials":135,"cells":1466},{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1473,"PHASE4":1479,"NA":1481},{"trials":1468,"activeCount":100},[],{"trials":1470,"activeCount":100},[],{"trials":1472,"activeCount":100},[],{"trials":1474,"activeCount":100},[1475],{"nctId":1450,"briefTitle":1451,"status":192,"phases":1476,"primaryCompletion":1453,"completion":1454,"start":1455,"enrollment":1456,"conditions":1477,"interventions":1478},[90],[1458],[1439,1460],{"trials":1480,"activeCount":100},[],{"trials":1482,"activeCount":100},[],{"intervention":1484,"totalTrials":135,"cells":1485},"Pimecrolimus",{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1492,"PHASE4":1502,"NA":1504},{"trials":1487,"activeCount":100},[],{"trials":1489,"activeCount":100},[],{"trials":1491,"activeCount":100},[],{"trials":1493,"activeCount":100},[1494],{"nctId":1495,"briefTitle":1496,"status":192,"phases":1497,"primaryCompletion":1165,"completion":1165,"start":1498,"enrollment":566,"conditions":1499,"interventions":1501},"NCT00130572","Efficacy of Elidel Cream on Erosive Oral Lichen Planus",[90],"2004-06",[1500],"Lichen Planus, Oral",[1484],{"trials":1503,"activeCount":100},[],{"trials":1505,"activeCount":100},[],{"intervention":1507,"totalTrials":135,"cells":1508},"local intracoronary dosis of Paclitaxel",{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1513,"PHASE3":1515,"PHASE4":1528,"NA":1530},{"trials":1510,"activeCount":100},[],{"trials":1512,"activeCount":100},[],{"trials":1514,"activeCount":100},[],{"trials":1516,"activeCount":100},[1517],{"nctId":1518,"briefTitle":1519,"status":834,"phases":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":1524,"interventions":1527},"NCT00396929","Efficiency of a New Therapy to Treat Stenosis of Coronary Vessels in Comparison With Two Already Admitted Therapies",[90],"2007-07","2005-08",204,[1525,1526],"Stable or Unstable Angina Pectoris","Myocardial Ischemia",[1507],{"trials":1529,"activeCount":100},[],{"trials":1531,"activeCount":100},[],{"intervention":1533,"totalTrials":135,"cells":1534},"Allopurinol",{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1539,"PHASE3":1541,"PHASE4":1555,"NA":1557},{"trials":1536,"activeCount":100},[],{"trials":1538,"activeCount":100},[],{"trials":1540,"activeCount":100},[],{"trials":1542,"activeCount":100},[1543],{"nctId":1544,"briefTitle":1545,"status":834,"phases":1546,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":1550,"interventions":1553},"NCT03162653","Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome",[90],"2026-01-31","2018-03-25",760,[1551,1552],"Encephalopathy, Hypoxic-Ischemic","Infant, Newborn, Diseases",[1533,1554],"Mannitol",{"trials":1556,"activeCount":100},[],{"trials":1558,"activeCount":100},[],{"intervention":1554,"totalTrials":135,"cells":1560},{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1565,"PHASE3":1567,"PHASE4":1573,"NA":1575},{"trials":1562,"activeCount":100},[],{"trials":1564,"activeCount":100},[],{"trials":1566,"activeCount":100},[],{"trials":1568,"activeCount":100},[1569],{"nctId":1544,"briefTitle":1545,"status":834,"phases":1570,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":1571,"interventions":1572},[90],[1551,1552],[1533,1554],{"trials":1574,"activeCount":100},[],{"trials":1576,"activeCount":100},[],{"intervention":1578,"totalTrials":135,"cells":1579},"clopidogrel",{"EARLY_PHASE1":1580,"PHASE1":1582,"PHASE2":1584,"PHASE3":1586,"PHASE4":1598,"NA":1600},{"trials":1581,"activeCount":100},[],{"trials":1583,"activeCount":100},[],{"trials":1585,"activeCount":100},[],{"trials":1587,"activeCount":100},[1588],{"nctId":1589,"briefTitle":1590,"status":192,"phases":1591,"primaryCompletion":1592,"completion":1593,"start":1069,"enrollment":1594,"conditions":1595,"interventions":1597},"NCT00163267","Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel",[89,90],"2009-12","2011-04",80,[1596],"Peripheral Vascular Diseases",[1578],{"trials":1599,"activeCount":100},[],{"trials":1601,"activeCount":100},[],{"intervention":1603,"totalTrials":135,"cells":1604},"trofosfamide, idarubicin, etoposide",{"EARLY_PHASE1":1605,"PHASE1":1607,"PHASE2":1609,"PHASE3":1611,"PHASE4":1623,"NA":1625},{"trials":1606,"activeCount":100},[],{"trials":1608,"activeCount":100},[],{"trials":1610,"activeCount":100},[],{"trials":1612,"activeCount":100},[1613],{"nctId":1614,"briefTitle":1615,"status":192,"phases":1616,"primaryCompletion":1617,"completion":1617,"start":1618,"enrollment":1619,"conditions":1620,"interventions":1622},"NCT00876031","Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma",[90],"2022-06-30","2009-07-01",195,[1621],"Soft Tissue Sarcoma",[1603],{"trials":1624,"activeCount":100},[],{"trials":1626,"activeCount":100},[],{"intervention":1628,"totalTrials":135,"cells":1629},"Balloon Angioplasty with or without drug administration",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1636,"PHASE4":1648,"NA":1650},{"trials":1631,"activeCount":100},[],{"trials":1633,"activeCount":100},[],{"trials":1635,"activeCount":100},[],{"trials":1637,"activeCount":100},[1638],{"nctId":1639,"briefTitle":1640,"status":834,"phases":1641,"completion":1642,"start":1643,"enrollment":1644,"conditions":1645,"interventions":1647},"NCT00156624","Thunder Trial - Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries",[89,90],"2007-10","2004-07",135,[1646],"Arterial Occlusive Diseases",[1628],{"trials":1649,"activeCount":100},[],{"trials":1651,"activeCount":100},[],{"intervention":1653,"totalTrials":135,"cells":1654},"dornase alfa",{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1659,"PHASE3":1661,"PHASE4":1673,"NA":1675},{"trials":1656,"activeCount":100},[],{"trials":1658,"activeCount":100},[],{"trials":1660,"activeCount":100},[],{"trials":1662,"activeCount":100},[1663],{"nctId":1664,"briefTitle":1665,"status":834,"phases":1666,"completion":1667,"start":1668,"enrollment":1669,"conditions":1670,"interventions":1672},"NCT00204685","Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase Alfa",[89,90],"2006-07","2003-08",540,[1671],"Long Term Ventilation",[1653],{"trials":1674,"activeCount":100},[],{"trials":1676,"activeCount":100},[],{"intervention":1678,"totalTrials":135,"cells":1679},"positive cytology with HIPEC",{"EARLY_PHASE1":1680,"PHASE1":1682,"PHASE2":1684,"PHASE3":1686,"PHASE4":1698,"NA":1700},{"trials":1681,"activeCount":100},[],{"trials":1683,"activeCount":100},[],{"trials":1685,"activeCount":100},[],{"trials":1687,"activeCount":100},[1688],{"nctId":1689,"briefTitle":1690,"status":1093,"phases":1691,"primaryCompletion":1692,"completion":1692,"start":1693,"enrollment":1028,"conditions":1694,"interventions":1697},"NCT01683864","Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer",[89,90],"2015-05","2012-09",[1695,1696],"Gastric Cancer","Peritoneal Carcinomatosis",[1678],{"trials":1699,"activeCount":100},[],{"trials":1701,"activeCount":100},[],{"intervention":1703,"totalTrials":135,"cells":1704},"Cyclosporin A",{"EARLY_PHASE1":1705,"PHASE1":1707,"PHASE2":1709,"PHASE3":1711,"PHASE4":1727,"NA":1729},{"trials":1706,"activeCount":100},[],{"trials":1708,"activeCount":100},[],{"trials":1710,"activeCount":100},[],{"trials":1712,"activeCount":100},[1713],{"nctId":1714,"briefTitle":1715,"status":192,"phases":1716,"primaryCompletion":1717,"completion":1717,"start":1718,"enrollment":1719,"conditions":1720,"interventions":1725},"NCT00167583","Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)",[90],"2014-12","2004-11",37,[1721,1722,1723,1724],"Behcet's Disease","Panuveitis","Posterior Uveitis","Retinal Vasculitis",[1703,1726],"Interferon-alpha2a",{"trials":1728,"activeCount":100},[],{"trials":1730,"activeCount":100},[],{"intervention":1726,"totalTrials":135,"cells":1732},{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1737,"PHASE3":1739,"PHASE4":1745,"NA":1747},{"trials":1734,"activeCount":100},[],{"trials":1736,"activeCount":100},[],{"trials":1738,"activeCount":100},[],{"trials":1740,"activeCount":100},[1741],{"nctId":1714,"briefTitle":1715,"status":192,"phases":1742,"primaryCompletion":1717,"completion":1717,"start":1718,"enrollment":1719,"conditions":1743,"interventions":1744},[90],[1721,1722,1723,1724],[1703,1726],{"trials":1746,"activeCount":100},[],{"trials":1748,"activeCount":100},[],{"intervention":1750,"totalTrials":135,"cells":1751},"Dexamethasone-dihydrogenphosphate",{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1758,"PHASE4":1767,"NA":1769},{"trials":1753,"activeCount":100},[],{"trials":1755,"activeCount":100},[],{"trials":1757,"activeCount":100},[],{"trials":1759,"activeCount":100},[1760],{"nctId":1761,"briefTitle":1762,"status":192,"phases":1763,"primaryCompletion":1667,"completion":1521,"start":1429,"enrollment":1430,"conditions":1764,"interventions":1766},"NCT00335920","Safety and Efficacy of Intratympanic Application of Dexamethasone Via Catheter in Patients With Sudden Hearing Loss",[90],[1765],"Sudden Deafness",[1750],{"trials":1768,"activeCount":100},[],{"trials":1770,"activeCount":100},[],{"intervention":1772,"totalTrials":135,"cells":1773},"Amiloride",{"EARLY_PHASE1":1774,"PHASE1":1776,"PHASE2":1778,"PHASE3":1780,"PHASE4":1795,"NA":1797},{"trials":1775,"activeCount":100},[],{"trials":1777,"activeCount":100},[],{"trials":1779,"activeCount":100},[],{"trials":1781,"activeCount":100},[1782],{"nctId":1783,"briefTitle":1784,"status":1093,"phases":1785,"primaryCompletion":1786,"completion":1787,"start":1788,"enrollment":566,"conditions":1789,"interventions":1793},"NCT05079789","Amiloride in Nephrotic Syndrome",[90],"2022-11-05","2022-11-20","2020-06-08",[1790,1791,1792],"Nephrotic Syndrome","Edema","Sodium Retention",[1772,1794],"Furosemide",{"trials":1796,"activeCount":100},[],{"trials":1798,"activeCount":100},[],{"intervention":1794,"totalTrials":135,"cells":1800},{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1805,"PHASE3":1807,"PHASE4":1813,"NA":1815},{"trials":1802,"activeCount":100},[],{"trials":1804,"activeCount":100},[],{"trials":1806,"activeCount":100},[],{"trials":1808,"activeCount":100},[1809],{"nctId":1783,"briefTitle":1784,"status":1093,"phases":1810,"primaryCompletion":1786,"completion":1787,"start":1788,"enrollment":566,"conditions":1811,"interventions":1812},[90],[1790,1791,1792],[1772,1794],{"trials":1814,"activeCount":100},[],{"trials":1816,"activeCount":100},[],{"intervention":1818,"totalTrials":135,"cells":1819},"Herbal-based medication",{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1824,"PHASE3":1826,"PHASE4":1838,"NA":1840},{"trials":1821,"activeCount":100},[],{"trials":1823,"activeCount":100},[],{"trials":1825,"activeCount":100},[],{"trials":1827,"activeCount":100},[1828],{"nctId":1829,"briefTitle":1830,"status":192,"phases":1831,"primaryCompletion":1832,"completion":1040,"start":1833,"enrollment":1834,"conditions":1835,"interventions":1837},"NCT02345447","Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence",[90],"2015-10","2013-10",296,[1836],"Acute Otitis Media",[1818],{"trials":1839,"activeCount":100},[],{"trials":1841,"activeCount":100},[],{"intervention":1843,"totalTrials":135,"cells":1844},"insulin Levemir",{"EARLY_PHASE1":1845,"PHASE1":1847,"PHASE2":1849,"PHASE3":1851,"PHASE4":1863,"NA":1865},{"trials":1846,"activeCount":100},[],{"trials":1848,"activeCount":100},[],{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":100},[1853],{"nctId":1854,"briefTitle":1855,"status":1093,"phases":1856,"start":1857,"enrollment":1858,"conditions":1859,"interventions":1861},"NCT00656422","Weight Gain, Eating Patterns, and Development of Body Composition During Initiation of Basal Insulin Therapy in Patients With Type 2 Diabetes: A Comparison of Insulin Detemir and Insulin Glargine",[90],"2007-11",66,[1860,15],"Diabetes",[1843,1862],"insulin Lantus",{"trials":1864,"activeCount":100},[],{"trials":1866,"activeCount":100},[],{"intervention":1862,"totalTrials":135,"cells":1868},{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1875,"PHASE4":1881,"NA":1883},{"trials":1870,"activeCount":100},[],{"trials":1872,"activeCount":100},[],{"trials":1874,"activeCount":100},[],{"trials":1876,"activeCount":100},[1877],{"nctId":1854,"briefTitle":1855,"status":1093,"phases":1878,"start":1857,"enrollment":1858,"conditions":1879,"interventions":1880},[90],[1860,15],[1843,1862],{"trials":1882,"activeCount":100},[],{"trials":1884,"activeCount":100},[],{"intervention":1886,"totalTrials":135,"cells":1887},"St. John's Wort",{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1892,"PHASE3":1894,"PHASE4":1905,"NA":1907},{"trials":1889,"activeCount":100},[],{"trials":1891,"activeCount":100},[],{"trials":1893,"activeCount":100},[],{"trials":1895,"activeCount":100},[1896],{"nctId":1897,"briefTitle":1898,"status":834,"phases":1899,"primaryCompletion":1900,"completion":1901,"start":1902,"enrollment":827,"conditions":1903,"interventions":1904},"NCT02840331","Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis",[90],"2019-12","2020-07","2017-07-31",[1696],[1886],{"trials":1906,"activeCount":100},[],{"trials":1908,"activeCount":100},[],{"intervention":1910,"totalTrials":135,"cells":1911},"Iloprost",{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1916,"PHASE3":1918,"PHASE4":1931,"NA":1933},{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[],{"trials":1917,"activeCount":100},[],{"trials":1919,"activeCount":100},[1920],{"nctId":1921,"briefTitle":1922,"status":192,"phases":1923,"primaryCompletion":1924,"completion":1925,"start":1926,"enrollment":155,"conditions":1927,"interventions":1929},"NCT03111212","Iloprost in Acute Respiratory Distress Syndrome",[90],"2021-05-14","2021-08-14","2019-06-25",[1928],"Respiratory Distress Syndrome, Adult",[1910,1930],"control",{"trials":1932,"activeCount":100},[],{"trials":1934,"activeCount":100},[],{"intervention":1930,"totalTrials":135,"cells":1936},{"EARLY_PHASE1":1937,"PHASE1":1939,"PHASE2":1941,"PHASE3":1943,"PHASE4":1949,"NA":1951},{"trials":1938,"activeCount":100},[],{"trials":1940,"activeCount":100},[],{"trials":1942,"activeCount":100},[],{"trials":1944,"activeCount":100},[1945],{"nctId":1921,"briefTitle":1922,"status":192,"phases":1946,"primaryCompletion":1924,"completion":1925,"start":1926,"enrollment":155,"conditions":1947,"interventions":1948},[90],[1928],[1910,1930],{"trials":1950,"activeCount":100},[],{"trials":1952,"activeCount":100},[],{"intervention":1954,"totalTrials":135,"cells":1955},"Apixaban",{"EARLY_PHASE1":1956,"PHASE1":1958,"PHASE2":1960,"PHASE3":1962,"PHASE4":1975,"NA":1977},{"trials":1957,"activeCount":100},[],{"trials":1959,"activeCount":100},[],{"trials":1961,"activeCount":100},[],{"trials":1963,"activeCount":100},[1964],{"nctId":1965,"briefTitle":1966,"status":192,"phases":1967,"primaryCompletion":1968,"completion":130,"start":1969,"enrollment":1970,"conditions":1971,"interventions":1973},"NCT02427126","Apixaban for Treatment of Embolic Stroke of Undetermined Source",[90],"2020-08","2015-12",352,[1972],"Embolic Stroke of Undetermined Source",[1954,1974],"Aspirin",{"trials":1976,"activeCount":100},[],{"trials":1978,"activeCount":100},[],{"intervention":1974,"totalTrials":135,"cells":1980},{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1985,"PHASE3":1987,"PHASE4":1993,"NA":1995},{"trials":1982,"activeCount":100},[],{"trials":1984,"activeCount":100},[],{"trials":1986,"activeCount":100},[],{"trials":1988,"activeCount":100},[1989],{"nctId":1965,"briefTitle":1966,"status":192,"phases":1990,"primaryCompletion":1968,"completion":130,"start":1969,"enrollment":1970,"conditions":1991,"interventions":1992},[90],[1972],[1954,1974],{"trials":1994,"activeCount":100},[],{"trials":1996,"activeCount":100},[],{"intervention":1998,"totalTrials":135,"cells":1999},"Tenecteplase",{"EARLY_PHASE1":2000,"PHASE1":2002,"PHASE2":2004,"PHASE3":2006,"PHASE4":2019,"NA":2021},{"trials":2001,"activeCount":100},[],{"trials":2003,"activeCount":100},[],{"trials":2005,"activeCount":100},[],{"trials":2007,"activeCount":100},[2008],{"nctId":2009,"briefTitle":2010,"status":1093,"phases":2011,"primaryCompletion":2012,"completion":2013,"start":2014,"enrollment":2015,"conditions":2016,"interventions":2018},"NCT04965038","Early Reperfusion Therapy With Intravenous Thrombolysis for Recovery of VISION in Acute Central Retinal Artery Occlusion",[90],"2026-03-23","2026-04-29","2022-10-10",127,[2017],"Central Retinal Artery Occlusion",[1998],{"trials":2020,"activeCount":100},[],{"trials":2022,"activeCount":100},[],{"intervention":2024,"totalTrials":135,"cells":2025},"Antibiotic",{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2030,"PHASE3":2032,"PHASE4":2044,"NA":2046},{"trials":2027,"activeCount":100},[],{"trials":2029,"activeCount":100},[],{"trials":2031,"activeCount":100},[],{"trials":2033,"activeCount":100},[2034],{"nctId":2035,"briefTitle":2036,"status":192,"phases":2037,"primaryCompletion":2038,"completion":2038,"start":2039,"enrollment":2040,"conditions":2041,"interventions":2043},"NCT02793193","Effect of Probiotics on Central Nervous System Functions in Humans",[89,90],"2018-01","2016-07",54,[2042],"Social Stress",[2024],{"trials":2045,"activeCount":100},[],{"trials":2047,"activeCount":100},[],{"intervention":2049,"totalTrials":135,"cells":2050},"ReoPro",{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2057,"PHASE4":2066,"NA":2068},{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"trials":2056,"activeCount":100},[],{"trials":2058,"activeCount":100},[2059],{"nctId":2060,"briefTitle":2061,"status":834,"phases":2062,"completion":1592,"start":1070,"enrollment":2063,"conditions":2064,"interventions":2065},"NCT00156611","Rio Trial - ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease",[89,90],420,[1646],[2049],{"trials":2067,"activeCount":100},[],{"trials":2069,"activeCount":100},[],{"intervention":2071,"totalTrials":135,"cells":2072},"Infanrix + Prevenar 13",{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2079,"PHASE4":2092,"NA":2094},{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":100},[],{"trials":2078,"activeCount":100},[],{"trials":2080,"activeCount":100},[2081],{"nctId":2082,"briefTitle":2083,"status":192,"phases":2084,"primaryCompletion":2085,"completion":2086,"start":2087,"enrollment":16,"conditions":2088,"interventions":2091},"NCT02640703","Effect of Morning vs. Evening Vaccination on Hypoxia and Bradycardia of Preterm Infants: a Randomised Controled Trial",[90],"2016-12","2017-05","2015-03",[2089,2090],"Premature Birth","Intermittent Hypoxiema",[2071],{"trials":2093,"activeCount":100},[],{"trials":2095,"activeCount":100},[],{"intervention":2097,"totalTrials":135,"cells":2098},"pegylated interferon-alpha-2a",{"EARLY_PHASE1":2099,"PHASE1":2101,"PHASE2":2103,"PHASE3":2105,"PHASE4":2118,"NA":2120},{"trials":2100,"activeCount":100},[],{"trials":2102,"activeCount":100},[],{"trials":2104,"activeCount":100},[],{"trials":2106,"activeCount":100},[2107],{"nctId":2108,"briefTitle":2109,"status":192,"phases":2110,"primaryCompletion":2111,"completion":2085,"start":2112,"enrollment":2113,"conditions":2114,"interventions":2116},"NCT00204529","Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB",[90],"2013-05","2004-10",901,[2115],"Melanoma",[2097,2117],"interferon-alpha-2a",{"trials":2119,"activeCount":100},[],{"trials":2121,"activeCount":100},[],{"intervention":2117,"totalTrials":135,"cells":2123},{"EARLY_PHASE1":2124,"PHASE1":2126,"PHASE2":2128,"PHASE3":2130,"PHASE4":2136,"NA":2138},{"trials":2125,"activeCount":100},[],{"trials":2127,"activeCount":100},[],{"trials":2129,"activeCount":100},[],{"trials":2131,"activeCount":100},[2132],{"nctId":2108,"briefTitle":2109,"status":192,"phases":2133,"primaryCompletion":2111,"completion":2085,"start":2112,"enrollment":2113,"conditions":2134,"interventions":2135},[90],[2115],[2097,2117],{"trials":2137,"activeCount":100},[],{"trials":2139,"activeCount":100},[],{"intervention":2141,"totalTrials":135,"cells":2142},"Hydroxychloroquine Sulfate",{"EARLY_PHASE1":2143,"PHASE1":2145,"PHASE2":2147,"PHASE3":2149,"PHASE4":2160,"NA":2162},{"trials":2144,"activeCount":100},[],{"trials":2146,"activeCount":100},[],{"trials":2148,"activeCount":100},[],{"trials":2150,"activeCount":100},[2151],{"nctId":2152,"briefTitle":2153,"status":1093,"phases":2154,"primaryCompletion":2155,"completion":2155,"start":2156,"enrollment":9,"conditions":2157,"interventions":2159},"NCT04342221","Hydroxychloroquine for COVID-19",[90],"2021-02-26","2020-03-29",[2158],"COVID-19, Hydroxychloroquine Sulfate",[2141],{"trials":2161,"activeCount":100},[],{"trials":2163,"activeCount":100},[],{"intervention":1045,"totalTrials":1028,"cells":2165},{"EARLY_PHASE1":2166,"PHASE1":2168,"PHASE2":2170,"PHASE3":2193,"PHASE4":2195,"NA":2197},{"trials":2167,"activeCount":100},[],{"trials":2169,"activeCount":100},[],{"trials":2171,"activeCount":100},[2172,2176,2180],{"nctId":1037,"briefTitle":1038,"status":834,"phases":2173,"primaryCompletion":1040,"completion":1040,"start":1041,"enrollment":775,"conditions":2174,"interventions":2175},[88,89],[1043],[1045,1046,1047,1027,1048,1049],{"nctId":1051,"briefTitle":1052,"status":192,"phases":2177,"primaryCompletion":1054,"completion":1055,"start":1056,"enrollment":707,"conditions":2178,"interventions":2179},[89],[1058],[1060,1027],{"nctId":2181,"briefTitle":2182,"status":834,"phases":2183,"primaryCompletion":1040,"completion":2184,"start":2185,"enrollment":2186,"conditions":2187,"interventions":2190},"NCT02429440","Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides",[88,89],"2018-06","2005-05",40,[2188,2189],"Renal Cell Cancer","Advanced Renal Cell Cancer",[2191,2192,1046],"peptide vaccine","Granulocyte Macrophage Colony Stimulating Factor",{"trials":2194,"activeCount":100},[],{"trials":2196,"activeCount":100},[],{"trials":2198,"activeCount":100},[],{"intervention":2200,"totalTrials":96,"cells":2201},"Chemotherapy",{"EARLY_PHASE1":2202,"PHASE1":2204,"PHASE2":2206,"PHASE3":2235,"PHASE4":2237,"NA":2239},{"trials":2203,"activeCount":100},[],{"trials":2205,"activeCount":100},[],{"trials":2207,"activeCount":100},[2208,2222],{"nctId":2209,"briefTitle":2210,"status":192,"phases":2211,"primaryCompletion":2212,"completion":2212,"start":2213,"enrollment":2214,"conditions":2215,"interventions":2221},"NCT02353858","Preoperative Radiochemotherapy With Hyperthermia for Locally Advanced Rectal Cancer",[89],"2017-12","2012-08",78,[982,2216,2217,2218,2219,2220],"Locally Advanced Rectal Cancer","Hyperthermia","Hyperthermic Radiochemotherapy","Hyperthermic Chemoradiotherapy","Deep Regional Hyperthermia",[2200],{"nctId":2223,"briefTitle":2224,"status":834,"phases":2225,"primaryCompletion":2226,"completion":2227,"start":2228,"enrollment":2229,"conditions":2230,"interventions":2234},"NCT03561142","Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy.",[89],"2020-04-16","2024-04-16","2018-06-15",94,[982,2231,2232,2233],"Rectal Neoplasms","Rectal Cancer Stage II","Rectal Cancer Stage III",[2200],{"trials":2236,"activeCount":100},[],{"trials":2238,"activeCount":100},[],{"trials":2240,"activeCount":100},[],{"intervention":2242,"totalTrials":96,"cells":2243},"Ipilimumab",{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2272,"PHASE4":2274,"NA":2276},{"trials":2245,"activeCount":100},[],{"trials":2247,"activeCount":100},[],{"trials":2249,"activeCount":100},[2250,2261],{"nctId":2251,"briefTitle":2252,"status":1093,"phases":2253,"primaryCompletion":2254,"completion":2254,"start":2255,"enrollment":33,"conditions":2256,"interventions":2259},"NCT03728465","Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma",[89],"2021-01-01","2018-04-10",[2257,2258],"Metastatic Melanoma","Brain Metastases",[2260,2242],"Nivolumab",{"nctId":2262,"briefTitle":2263,"status":192,"phases":2264,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":2268,"conditions":2269,"interventions":2270},"NCT01480323","A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2",[89],"2014-09","2015-06","2012-02",15,[32],[2271,2242],"Interleukin-2",{"trials":2273,"activeCount":100},[],{"trials":2275,"activeCount":100},[],{"trials":2277,"activeCount":100},[],{"intervention":2279,"totalTrials":96,"cells":2280},"Vemurafenib",{"EARLY_PHASE1":2281,"PHASE1":2283,"PHASE2":2285,"PHASE3":2308,"PHASE4":2310,"NA":2312},{"trials":2282,"activeCount":100},[],{"trials":2284,"activeCount":100},[],{"trials":2286,"activeCount":100},[2287,2297],{"nctId":2288,"briefTitle":2289,"status":1093,"phases":2290,"primaryCompletion":1717,"completion":2291,"start":2292,"enrollment":25,"conditions":2293,"interventions":2295},"NCT02052193","Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa\u002FIIb Study",[89],"2014-12-15","2014-01",[2294],"Metastatic Melanoma (Carrying BRAF V600 Mutation)",[2296,2279],"Dabrafenib",{"nctId":2298,"briefTitle":2299,"status":1093,"phases":2300,"primaryCompletion":2301,"completion":2301,"start":2302,"enrollment":2303,"conditions":2304,"interventions":2305},"NCT02303951","Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC",[89],"2020-05-14","2015-01-22",47,[32],[2279,2306,2307],"Cobimetinib","Atezolizumab",{"trials":2309,"activeCount":100},[],{"trials":2311,"activeCount":100},[],{"trials":2313,"activeCount":100},[],{"intervention":2271,"totalTrials":96,"cells":2315},{"EARLY_PHASE1":2316,"PHASE1":2318,"PHASE2":2320,"PHASE3":2334,"PHASE4":2336,"NA":2338},{"trials":2317,"activeCount":100},[],{"trials":2319,"activeCount":100},[],{"trials":2321,"activeCount":100},[2322,2326],{"nctId":2262,"briefTitle":2263,"status":192,"phases":2323,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":2268,"conditions":2324,"interventions":2325},[89],[32],[2271,2242],{"nctId":2327,"briefTitle":2328,"status":192,"phases":2329,"primaryCompletion":2330,"completion":1592,"start":1668,"enrollment":2331,"conditions":2332,"interventions":2333},"NCT00204581","Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases",[89],"2009-01",51,[2115],[2271],{"trials":2335,"activeCount":100},[],{"trials":2337,"activeCount":100},[],{"trials":2339,"activeCount":100},[],{"intervention":1048,"totalTrials":96,"cells":2341},{"EARLY_PHASE1":2342,"PHASE1":2344,"PHASE2":2346,"PHASE3":2360,"PHASE4":2362,"NA":2364},{"trials":2343,"activeCount":100},[],{"trials":2345,"activeCount":100},[],{"trials":2347,"activeCount":100},[2348,2356],{"nctId":2349,"briefTitle":2350,"status":192,"phases":2351,"completion":2352,"start":1643,"enrollment":566,"conditions":2353,"interventions":2354},"NCT00204607","Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I\u002FII Trial in Melanoma Patients",[88,89],"2007-01",[32],[1048,2355],"GM-CSF s.c.",{"nctId":1037,"briefTitle":1038,"status":834,"phases":2357,"primaryCompletion":1040,"completion":1040,"start":1041,"enrollment":775,"conditions":2358,"interventions":2359},[88,89],[1043],[1045,1046,1047,1027,1048,1049],{"trials":2361,"activeCount":100},[],{"trials":2363,"activeCount":100},[],{"trials":2365,"activeCount":100},[],{"intervention":1046,"totalTrials":96,"cells":2367},{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2372,"PHASE3":2382,"PHASE4":2384,"NA":2386},{"trials":2369,"activeCount":100},[],{"trials":2371,"activeCount":100},[],{"trials":2373,"activeCount":100},[2374,2378],{"nctId":1037,"briefTitle":1038,"status":834,"phases":2375,"primaryCompletion":1040,"completion":1040,"start":1041,"enrollment":775,"conditions":2376,"interventions":2377},[88,89],[1043],[1045,1046,1047,1027,1048,1049],{"nctId":2181,"briefTitle":2182,"status":834,"phases":2379,"primaryCompletion":1040,"completion":2184,"start":2185,"enrollment":2186,"conditions":2380,"interventions":2381},[88,89],[2188,2189],[2191,2192,1046],{"trials":2383,"activeCount":100},[],{"trials":2385,"activeCount":100},[],{"trials":2387,"activeCount":100},[],{"intervention":1047,"totalTrials":96,"cells":2389},{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2394,"PHASE3":2404,"PHASE4":2406,"NA":2408},{"trials":2391,"activeCount":100},[],{"trials":2393,"activeCount":100},[],{"trials":2395,"activeCount":100},[2396,2400],{"nctId":1037,"briefTitle":1038,"status":834,"phases":2397,"primaryCompletion":1040,"completion":1040,"start":1041,"enrollment":775,"conditions":2398,"interventions":2399},[88,89],[1043],[1045,1046,1047,1027,1048,1049],{"nctId":2181,"briefTitle":2182,"status":834,"phases":2401,"primaryCompletion":1040,"completion":2184,"start":2185,"enrollment":2186,"conditions":2402,"interventions":2403},[88,89],[2188,2189],[2191,2192,1046],{"trials":2405,"activeCount":100},[],{"trials":2407,"activeCount":100},[],{"trials":2409,"activeCount":100},[],{"intervention":2411,"totalTrials":135,"cells":2412},"Bendamustin",{"EARLY_PHASE1":2413,"PHASE1":2415,"PHASE2":2417,"PHASE3":2428,"PHASE4":2430,"NA":2432},{"trials":2414,"activeCount":100},[],{"trials":2416,"activeCount":100},[],{"trials":2418,"activeCount":100},[2419],{"nctId":2420,"briefTitle":2421,"status":192,"phases":2422,"completion":1095,"start":2423,"enrollment":2424,"conditions":2425,"interventions":2427},"NCT00204620","Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)",[89],"2002-03",28,[2426],"Sarcoma, Soft Tissue",[2411],{"trials":2429,"activeCount":100},[],{"trials":2431,"activeCount":100},[],{"trials":2433,"activeCount":100},[],{"intervention":2435,"totalTrials":135,"cells":2436},"pegfilgrastim",{"EARLY_PHASE1":2437,"PHASE1":2439,"PHASE2":2441,"PHASE3":2454,"PHASE4":2456,"NA":2458},{"trials":2438,"activeCount":100},[],{"trials":2440,"activeCount":100},[],{"trials":2442,"activeCount":100},[2443],{"nctId":2444,"briefTitle":2445,"status":192,"phases":2446,"primaryCompletion":2447,"completion":2448,"start":2449,"enrollment":2450,"conditions":2451,"interventions":2453},"NCT00306111","Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma",[89],"2008-12","2011-12","2006-01",14,[2452],"Non-Hodgkin Lymphoma",[2435],{"trials":2455,"activeCount":100},[],{"trials":2457,"activeCount":100},[],{"trials":2459,"activeCount":100},[],{"intervention":2461,"totalTrials":135,"cells":2462},"rivastigmine",{"EARLY_PHASE1":2463,"PHASE1":2465,"PHASE2":2467,"PHASE3":2479,"PHASE4":2481,"NA":2483},{"trials":2464,"activeCount":100},[],{"trials":2466,"activeCount":100},[],{"trials":2468,"activeCount":100},[2469],{"nctId":2470,"briefTitle":2471,"status":834,"phases":2472,"primaryCompletion":1592,"completion":2473,"start":2474,"enrollment":566,"conditions":2475,"interventions":2478},"NCT00522015","Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy",[89],"2010-02","2008-02",[2476,2477],"Progressive Supranuclear Palsy","Dementia",[2461],{"trials":2480,"activeCount":100},[],{"trials":2482,"activeCount":100},[],{"trials":2484,"activeCount":100},[],{"intervention":2486,"totalTrials":135,"cells":2487},"benzodiacepine",{"EARLY_PHASE1":2488,"PHASE1":2490,"PHASE2":2492,"PHASE3":2504,"PHASE4":2506,"NA":2508},{"trials":2489,"activeCount":100},[],{"trials":2491,"activeCount":100},[],{"trials":2493,"activeCount":100},[2494],{"nctId":2495,"briefTitle":2496,"status":192,"phases":2497,"completion":1428,"start":2498,"conditions":2499,"interventions":2503},"NCT00533286","Do Benzodiazepines Improve the Outcome of Mechanical Physiotherapy for Lumbar Disk Prolapse",[89],"2002-08",[2500,2501,2502],"Pain","Disability","Paresis",[2486],{"trials":2505,"activeCount":100},[],{"trials":2507,"activeCount":100},[],{"trials":2509,"activeCount":100},[],{"intervention":2511,"totalTrials":135,"cells":2512},"rM28",{"EARLY_PHASE1":2513,"PHASE1":2515,"PHASE2":2517,"PHASE3":2527,"PHASE4":2529,"NA":2531},{"trials":2514,"activeCount":100},[],{"trials":2516,"activeCount":100},[],{"trials":2518,"activeCount":100},[2519],{"nctId":2520,"briefTitle":2521,"status":192,"phases":2522,"primaryCompletion":1165,"completion":1165,"start":2523,"enrollment":135,"conditions":2524,"interventions":2525},"NCT00204594","Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28",[88,89],"2005-10",[32],[2511,2526],"autologous PBMCs",{"trials":2528,"activeCount":100},[],{"trials":2530,"activeCount":100},[],{"trials":2532,"activeCount":100},[],{"intervention":2526,"totalTrials":135,"cells":2534},{"EARLY_PHASE1":2535,"PHASE1":2537,"PHASE2":2539,"PHASE3":2545,"PHASE4":2547,"NA":2549},{"trials":2536,"activeCount":100},[],{"trials":2538,"activeCount":100},[],{"trials":2540,"activeCount":100},[2541],{"nctId":2520,"briefTitle":2521,"status":192,"phases":2542,"primaryCompletion":1165,"completion":1165,"start":2523,"enrollment":135,"conditions":2543,"interventions":2544},[88,89],[32],[2511,2526],{"trials":2546,"activeCount":100},[],{"trials":2548,"activeCount":100},[],{"trials":2550,"activeCount":100},[],{"intervention":2552,"totalTrials":135,"cells":2553},"mRNA coding for melanoma associated antigens",{"EARLY_PHASE1":2554,"PHASE1":2556,"PHASE2":2558,"PHASE3":2570,"PHASE4":2572,"NA":2574},{"trials":2555,"activeCount":100},[],{"trials":2557,"activeCount":100},[],{"trials":2559,"activeCount":100},[2560],{"nctId":2561,"briefTitle":2562,"status":192,"phases":2563,"primaryCompletion":2564,"completion":2565,"start":1428,"enrollment":2566,"conditions":2567,"interventions":2568},"NCT00204516","Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens",[88,89],"2011-08","2012-12",31,[32],[2552,2569],"GM-CSF",{"trials":2571,"activeCount":100},[],{"trials":2573,"activeCount":100},[],{"trials":2575,"activeCount":100},[],{"intervention":2569,"totalTrials":135,"cells":2577},{"EARLY_PHASE1":2578,"PHASE1":2580,"PHASE2":2582,"PHASE3":2588,"PHASE4":2590,"NA":2592},{"trials":2579,"activeCount":100},[],{"trials":2581,"activeCount":100},[],{"trials":2583,"activeCount":100},[2584],{"nctId":2561,"briefTitle":2562,"status":192,"phases":2585,"primaryCompletion":2564,"completion":2565,"start":1428,"enrollment":2566,"conditions":2586,"interventions":2587},[88,89],[32],[2552,2569],{"trials":2589,"activeCount":100},[],{"trials":2591,"activeCount":100},[],{"trials":2593,"activeCount":100},[],{"intervention":2595,"totalTrials":135,"cells":2596},"Bromocriptine",{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2601,"PHASE3":2611,"PHASE4":2613,"NA":2615},{"trials":2598,"activeCount":100},[],{"trials":2600,"activeCount":100},[],{"trials":2602,"activeCount":100},[2603],{"nctId":2604,"briefTitle":2605,"status":192,"phases":2606,"primaryCompletion":2607,"completion":2607,"start":2608,"enrollment":404,"conditions":2609,"interventions":2610},"NCT03525002","Dopamine Action on Metabolism in Relation to Genotype",[89],"2024-08-14","2018-05-03",[15],[2595],{"trials":2612,"activeCount":100},[],{"trials":2614,"activeCount":100},[],{"trials":2616,"activeCount":100},[],{"intervention":2618,"totalTrials":135,"cells":2619},"human interferon-α",{"EARLY_PHASE1":2620,"PHASE1":2622,"PHASE2":2624,"PHASE3":2635,"PHASE4":2637,"NA":2639},{"trials":2621,"activeCount":100},[],{"trials":2623,"activeCount":100},[],{"trials":2625,"activeCount":100},[2626],{"nctId":2627,"briefTitle":2628,"status":192,"phases":2629,"primaryCompletion":2630,"completion":2630,"start":1593,"enrollment":2631,"conditions":2632,"interventions":2634},"NCT01341158","NAM-Trial: Multiferon in Malignant Melanoma",[89],"2013-03",42,[2633],"Locoregional Metastases in Malignant Melanoma Stages IIIB\u002FC",[2618],{"trials":2636,"activeCount":100},[],{"trials":2638,"activeCount":100},[],{"trials":2640,"activeCount":100},[],{"intervention":2642,"totalTrials":135,"cells":2643},"Fludarabine, Thiotepa, Melphalan, Thymoglobuline",{"EARLY_PHASE1":2644,"PHASE1":2646,"PHASE2":2648,"PHASE3":2660,"PHASE4":2662,"NA":2664},{"trials":2645,"activeCount":100},[],{"trials":2647,"activeCount":100},[],{"trials":2649,"activeCount":100},[2650],{"nctId":2651,"briefTitle":2652,"status":1093,"phases":2653,"primaryCompletion":2654,"completion":2654,"start":2655,"enrollment":1430,"conditions":2656,"interventions":2659},"NCT00961142","Haploidentical Stem Cell Transplantation With CD3\u002FCD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia",[89],"2015-12-30","2009-06",[2657,2658],"Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia",[2642],{"trials":2661,"activeCount":100},[],{"trials":2663,"activeCount":100},[],{"trials":2665,"activeCount":100},[],{"intervention":2667,"totalTrials":135,"cells":2668},"Fludarabine",{"EARLY_PHASE1":2669,"PHASE1":2671,"PHASE2":2673,"PHASE3":2688,"PHASE4":2690,"NA":2692},{"trials":2670,"activeCount":100},[],{"trials":2672,"activeCount":100},[],{"trials":2674,"activeCount":100},[2675],{"nctId":2676,"briefTitle":2677,"status":192,"phases":2678,"primaryCompletion":2679,"completion":1302,"start":2680,"enrollment":2681,"conditions":2682,"interventions":2684},"NCT00202917","Haploidentical Transplantation With CD3\u002FCD19 Depleted Grafts in Patients With Hematologic Malignancies",[88,89],"2009-07","2004-02",61,[2683],"Hematologic Malignancies",[2667,2685,2686,2687],"Thiotepa","Melphalan","OKT-3",{"trials":2689,"activeCount":100},[],{"trials":2691,"activeCount":100},[],{"trials":2693,"activeCount":100},[],{"intervention":2685,"totalTrials":135,"cells":2695},{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2706,"PHASE4":2708,"NA":2710},{"trials":2697,"activeCount":100},[],{"trials":2699,"activeCount":100},[],{"trials":2701,"activeCount":100},[2702],{"nctId":2676,"briefTitle":2677,"status":192,"phases":2703,"primaryCompletion":2679,"completion":1302,"start":2680,"enrollment":2681,"conditions":2704,"interventions":2705},[88,89],[2683],[2667,2685,2686,2687],{"trials":2707,"activeCount":100},[],{"trials":2709,"activeCount":100},[],{"trials":2711,"activeCount":100},[],{"intervention":2686,"totalTrials":135,"cells":2713},{"EARLY_PHASE1":2714,"PHASE1":2716,"PHASE2":2718,"PHASE3":2724,"PHASE4":2726,"NA":2728},{"trials":2715,"activeCount":100},[],{"trials":2717,"activeCount":100},[],{"trials":2719,"activeCount":100},[2720],{"nctId":2676,"briefTitle":2677,"status":192,"phases":2721,"primaryCompletion":2679,"completion":1302,"start":2680,"enrollment":2681,"conditions":2722,"interventions":2723},[88,89],[2683],[2667,2685,2686,2687],{"trials":2725,"activeCount":100},[],{"trials":2727,"activeCount":100},[],{"trials":2729,"activeCount":100},[],{"intervention":2687,"totalTrials":135,"cells":2731},{"EARLY_PHASE1":2732,"PHASE1":2734,"PHASE2":2736,"PHASE3":2742,"PHASE4":2744,"NA":2746},{"trials":2733,"activeCount":100},[],{"trials":2735,"activeCount":100},[],{"trials":2737,"activeCount":100},[2738],{"nctId":2676,"briefTitle":2677,"status":192,"phases":2739,"primaryCompletion":2679,"completion":1302,"start":2680,"enrollment":2681,"conditions":2740,"interventions":2741},[88,89],[2683],[2667,2685,2686,2687],{"trials":2743,"activeCount":100},[],{"trials":2745,"activeCount":100},[],{"trials":2747,"activeCount":100},[],{"intervention":2749,"totalTrials":135,"cells":2750},"Pemetrexed",{"EARLY_PHASE1":2751,"PHASE1":2753,"PHASE2":2755,"PHASE3":2764,"PHASE4":2766,"NA":2768},{"trials":2752,"activeCount":100},[],{"trials":2754,"activeCount":100},[],{"trials":2756,"activeCount":100},[2757],{"nctId":2758,"briefTitle":2759,"status":192,"phases":2760,"primaryCompletion":2447,"completion":2447,"start":2352,"enrollment":2040,"conditions":2761,"interventions":2763},"NCT00427466","Pemetrexed in Patients With Soft Tissue Sarcoma",[89],[2762],"Sarcoma",[2749],{"trials":2765,"activeCount":100},[],{"trials":2767,"activeCount":100},[],{"trials":2769,"activeCount":100},[],{"intervention":2771,"totalTrials":135,"cells":2772},"Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells",{"EARLY_PHASE1":2773,"PHASE1":2775,"PHASE2":2777,"PHASE3":2789,"PHASE4":2791,"NA":2793},{"trials":2774,"activeCount":100},[],{"trials":2776,"activeCount":100},[],{"trials":2778,"activeCount":100},[2779],{"nctId":2780,"briefTitle":2781,"status":192,"phases":2782,"primaryCompletion":130,"completion":2783,"start":1693,"enrollment":1259,"conditions":2784,"interventions":2788},"NCT01895244","Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis",[89],"2024-06",[2785,2786,2787],"Scleroderma","Cardiac Involvement","Autologous Stem Cell Transplantation",[2771],{"trials":2790,"activeCount":100},[],{"trials":2792,"activeCount":100},[],{"trials":2794,"activeCount":100},[],{"intervention":2260,"totalTrials":135,"cells":2796},{"EARLY_PHASE1":2797,"PHASE1":2799,"PHASE2":2801,"PHASE3":2807,"PHASE4":2809,"NA":2811},{"trials":2798,"activeCount":100},[],{"trials":2800,"activeCount":100},[],{"trials":2802,"activeCount":100},[2803],{"nctId":2251,"briefTitle":2252,"status":1093,"phases":2804,"primaryCompletion":2254,"completion":2254,"start":2255,"enrollment":33,"conditions":2805,"interventions":2806},[89],[2257,2258],[2260,2242],{"trials":2808,"activeCount":100},[],{"trials":2810,"activeCount":100},[],{"trials":2812,"activeCount":100},[],{"intervention":2814,"totalTrials":135,"cells":2815},"abciximab",{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2820,"PHASE3":2831,"PHASE4":2833,"NA":2835},{"trials":2817,"activeCount":100},[],{"trials":2819,"activeCount":100},[],{"trials":2821,"activeCount":100},[2822],{"nctId":2823,"briefTitle":2824,"status":834,"phases":2825,"completion":2826,"start":2827,"conditions":2828,"interventions":2830},"NCT00163254","Below Study - Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee",[89],"2006-11","2003-09",[2829],"Patients Above 18 Years",[2814],{"trials":2832,"activeCount":100},[],{"trials":2834,"activeCount":100},[],{"trials":2836,"activeCount":100},[],{"intervention":2838,"totalTrials":135,"cells":2839},"Gemcitabine",{"EARLY_PHASE1":2840,"PHASE1":2842,"PHASE2":2844,"PHASE3":2856,"PHASE4":2858,"NA":2860},{"trials":2841,"activeCount":100},[],{"trials":2843,"activeCount":100},[],{"trials":2845,"activeCount":100},[2846],{"nctId":2847,"briefTitle":2848,"status":834,"phases":2849,"primaryCompletion":2850,"completion":2851,"start":2852,"enrollment":16,"conditions":2853,"interventions":2855},"NCT02863471","Study on Hyperthermic Intraperitoneal Chemotherapy After Resection of Pancreascarcinoma",[88,89],"2018-07","2018-10","2016-01",[2854],"Adenocarcinomas of the Pancreas",[2838],{"trials":2857,"activeCount":100},[],{"trials":2859,"activeCount":100},[],{"trials":2861,"activeCount":100},[],{"intervention":2863,"totalTrials":135,"cells":2864},"Empagliflozin 25mg",{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2869,"PHASE3":2881,"PHASE4":2883,"NA":2885},{"trials":2866,"activeCount":100},[],{"trials":2868,"activeCount":100},[],{"trials":2870,"activeCount":100},[2871],{"nctId":2872,"briefTitle":2873,"status":192,"phases":2874,"primaryCompletion":2875,"completion":2876,"start":2877,"enrollment":2631,"conditions":2878,"interventions":2880},"NCT03227484","Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes",[89],"2019-10-25","2019-11-18","2017-06-09",[120,2879],"Body Weight",[2863],{"trials":2882,"activeCount":100},[],{"trials":2884,"activeCount":100},[],{"trials":2886,"activeCount":100},[],{"intervention":2296,"totalTrials":135,"cells":2888},{"EARLY_PHASE1":2889,"PHASE1":2891,"PHASE2":2893,"PHASE3":2899,"PHASE4":2901,"NA":2903},{"trials":2890,"activeCount":100},[],{"trials":2892,"activeCount":100},[],{"trials":2894,"activeCount":100},[2895],{"nctId":2288,"briefTitle":2289,"status":1093,"phases":2896,"primaryCompletion":1717,"completion":2291,"start":2292,"enrollment":25,"conditions":2897,"interventions":2898},[89],[2294],[2296,2279],{"trials":2900,"activeCount":100},[],{"trials":2902,"activeCount":100},[],{"trials":2904,"activeCount":100},[],{"intervention":2906,"totalTrials":135,"cells":2907},"intraoperative hyperthermic intraperitoneal chemotherapy",{"EARLY_PHASE1":2908,"PHASE1":2910,"PHASE2":2912,"PHASE3":2924,"PHASE4":2926,"NA":2928},{"trials":2909,"activeCount":100},[],{"trials":2911,"activeCount":100},[],{"trials":2913,"activeCount":100},[2914],{"nctId":2915,"briefTitle":2916,"status":126,"phases":2917,"primaryCompletion":2918,"completion":2919,"start":2920,"enrollment":100,"conditions":2921,"interventions":2923},"NCT04180761","Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer",[89],"2022-03","2022-09","2019-11",[2922],"Gastric Neoplasms",[2906],{"trials":2925,"activeCount":100},[],{"trials":2927,"activeCount":100},[],{"trials":2929,"activeCount":100},[],{"intervention":2931,"totalTrials":135,"cells":2932},"Mitomycin C",{"EARLY_PHASE1":2933,"PHASE1":2935,"PHASE2":2937,"PHASE3":2950,"PHASE4":2952,"NA":2954},{"trials":2934,"activeCount":100},[],{"trials":2936,"activeCount":100},[],{"trials":2938,"activeCount":100},[2939],{"nctId":2940,"briefTitle":2941,"status":192,"phases":2942,"primaryCompletion":1096,"completion":1096,"start":2943,"conditions":2944,"interventions":2947},"NCT00289445","Study With Mitomycin c\u002F5-FU\u002FFA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)",[88,89],"1999-09",[2945,2946],"Gastrointestinal Neoplasms","Neoplasm Metastasis",[2931,2948,2949],"5-FU","Folinic acid",{"trials":2951,"activeCount":100},[],{"trials":2953,"activeCount":100},[],{"trials":2955,"activeCount":100},[],{"intervention":2948,"totalTrials":135,"cells":2957},{"EARLY_PHASE1":2958,"PHASE1":2960,"PHASE2":2962,"PHASE3":2968,"PHASE4":2970,"NA":2972},{"trials":2959,"activeCount":100},[],{"trials":2961,"activeCount":100},[],{"trials":2963,"activeCount":100},[2964],{"nctId":2940,"briefTitle":2941,"status":192,"phases":2965,"primaryCompletion":1096,"completion":1096,"start":2943,"conditions":2966,"interventions":2967},[88,89],[2945,2946],[2931,2948,2949],{"trials":2969,"activeCount":100},[],{"trials":2971,"activeCount":100},[],{"trials":2973,"activeCount":100},[],{"intervention":2949,"totalTrials":135,"cells":2975},{"EARLY_PHASE1":2976,"PHASE1":2978,"PHASE2":2980,"PHASE3":2986,"PHASE4":2988,"NA":2990},{"trials":2977,"activeCount":100},[],{"trials":2979,"activeCount":100},[],{"trials":2981,"activeCount":100},[2982],{"nctId":2940,"briefTitle":2941,"status":192,"phases":2983,"primaryCompletion":1096,"completion":1096,"start":2943,"conditions":2984,"interventions":2985},[88,89],[2945,2946],[2931,2948,2949],{"trials":2987,"activeCount":100},[],{"trials":2989,"activeCount":100},[],{"trials":2991,"activeCount":100},[],{"intervention":2993,"totalTrials":135,"cells":2994},"Tocilizumab Infusion RoAcemtra",{"EARLY_PHASE1":2995,"PHASE1":2997,"PHASE2":2999,"PHASE3":3011,"PHASE4":3013,"NA":3015},{"trials":2996,"activeCount":100},[],{"trials":2998,"activeCount":100},[],{"trials":3000,"activeCount":100},[3001],{"nctId":3002,"briefTitle":3003,"status":192,"phases":3004,"primaryCompletion":3005,"completion":3005,"start":3006,"enrollment":9,"conditions":3007,"interventions":3009},"NCT03446209","Tocilizumab for the Treatment of Familial Mediterranean Fever",[89],"2020-10-30","2018-04-23",[3008],"Familial Mediterranean Fever",[2993,3010],"0.9% physiological saline",{"trials":3012,"activeCount":100},[],{"trials":3014,"activeCount":100},[],{"trials":3016,"activeCount":100},[],{"intervention":3010,"totalTrials":135,"cells":3018},{"EARLY_PHASE1":3019,"PHASE1":3021,"PHASE2":3023,"PHASE3":3029,"PHASE4":3031,"NA":3033},{"trials":3020,"activeCount":100},[],{"trials":3022,"activeCount":100},[],{"trials":3024,"activeCount":100},[3025],{"nctId":3002,"briefTitle":3003,"status":192,"phases":3026,"primaryCompletion":3005,"completion":3005,"start":3006,"enrollment":9,"conditions":3027,"interventions":3028},[89],[3008],[2993,3010],{"trials":3030,"activeCount":100},[],{"trials":3032,"activeCount":100},[],{"trials":3034,"activeCount":100},[],{"intervention":3036,"totalTrials":135,"cells":3037},"Metformin",{"EARLY_PHASE1":3038,"PHASE1":3040,"PHASE2":3042,"PHASE3":3054,"PHASE4":3056,"NA":3058},{"trials":3039,"activeCount":100},[],{"trials":3041,"activeCount":100},[],{"trials":3043,"activeCount":100},[3044],{"nctId":3045,"briefTitle":3046,"status":126,"phases":3047,"primaryCompletion":3048,"completion":1968,"start":3049,"enrollment":100,"conditions":3050,"interventions":3053},"NCT03490019","Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement",[89],"2019-10","2018-04-01",[3051,3052],"Bardet-Biedl Syndrome","Visual Impairment",[3036],{"trials":3055,"activeCount":100},[],{"trials":3057,"activeCount":100},[],{"trials":3059,"activeCount":100},[],{"intervention":3061,"totalTrials":135,"cells":3062},"amitriptyline",{"EARLY_PHASE1":3063,"PHASE1":3065,"PHASE2":3067,"PHASE3":3080,"PHASE4":3082,"NA":3084},{"trials":3064,"activeCount":100},[],{"trials":3066,"activeCount":100},[],{"trials":3068,"activeCount":100},[3069],{"nctId":3070,"briefTitle":3071,"status":192,"phases":3072,"completion":1521,"start":3073,"enrollment":3074,"conditions":3075,"interventions":3079},"NCT00515229","Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo",[89],"2006-10",18,[3076,3077,3078],"Cystic Fibrosis","Infection","Pseudomonas Aeruginosa",[3061],{"trials":3081,"activeCount":100},[],{"trials":3083,"activeCount":100},[],{"trials":3085,"activeCount":100},[],{"intervention":3087,"totalTrials":135,"cells":3088},"[18F]FPyGal",{"EARLY_PHASE1":3089,"PHASE1":3091,"PHASE2":3093,"PHASE3":3105,"PHASE4":3107,"NA":3109},{"trials":3090,"activeCount":100},[],{"trials":3092,"activeCount":100},[],{"trials":3094,"activeCount":100},[3095],{"nctId":3096,"briefTitle":3097,"status":834,"phases":3098,"primaryCompletion":3099,"completion":2783,"start":3100,"enrollment":3101,"conditions":3102,"interventions":3104},"NCT04536454","Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside)",[88,89],"2023-06","2021-04-28",32,[3103],"Cancer",[3087],{"trials":3106,"activeCount":100},[],{"trials":3108,"activeCount":100},[],{"trials":3110,"activeCount":100},[],{"intervention":3112,"totalTrials":135,"cells":3113},"CoVAC-1",{"EARLY_PHASE1":3114,"PHASE1":3116,"PHASE2":3118,"PHASE3":3130,"PHASE4":3132,"NA":3134},{"trials":3115,"activeCount":100},[],{"trials":3117,"activeCount":100},[],{"trials":3119,"activeCount":100},[3120],{"nctId":3121,"briefTitle":3122,"status":192,"phases":3123,"primaryCompletion":3124,"completion":3125,"start":3126,"enrollment":2040,"conditions":3127,"interventions":3129},"NCT04954469","B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell\u002F Antibody Deficiency",[88,89],"2022-08-18","2023-04-30","2021-06-30",[3128],"Immune Deficiency Disease",[3112],{"trials":3131,"activeCount":100},[],{"trials":3133,"activeCount":100},[],{"trials":3135,"activeCount":100},[],{"intervention":3137,"totalTrials":135,"cells":3138},"Adriamycin",{"EARLY_PHASE1":3139,"PHASE1":3141,"PHASE2":3143,"PHASE3":3155,"PHASE4":3157,"NA":3159},{"trials":3140,"activeCount":100},[],{"trials":3142,"activeCount":100},[],{"trials":3144,"activeCount":100},[3145],{"nctId":3146,"briefTitle":3147,"status":192,"phases":3148,"completion":1095,"start":3149,"conditions":3150,"interventions":3151},"NCT00204646","Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS)",[89],"1999-02",[2426],[3137,3152,3153,3154],"Ifosfamide","Etoposide","Carboplatin",{"trials":3156,"activeCount":100},[],{"trials":3158,"activeCount":100},[],{"trials":3160,"activeCount":100},[],{"intervention":3152,"totalTrials":135,"cells":3162},{"EARLY_PHASE1":3163,"PHASE1":3165,"PHASE2":3167,"PHASE3":3173,"PHASE4":3175,"NA":3177},{"trials":3164,"activeCount":100},[],{"trials":3166,"activeCount":100},[],{"trials":3168,"activeCount":100},[3169],{"nctId":3146,"briefTitle":3147,"status":192,"phases":3170,"completion":1095,"start":3149,"conditions":3171,"interventions":3172},[89],[2426],[3137,3152,3153,3154],{"trials":3174,"activeCount":100},[],{"trials":3176,"activeCount":100},[],{"trials":3178,"activeCount":100},[],{"intervention":3153,"totalTrials":135,"cells":3180},{"EARLY_PHASE1":3181,"PHASE1":3183,"PHASE2":3185,"PHASE3":3191,"PHASE4":3193,"NA":3195},{"trials":3182,"activeCount":100},[],{"trials":3184,"activeCount":100},[],{"trials":3186,"activeCount":100},[3187],{"nctId":3146,"briefTitle":3147,"status":192,"phases":3188,"completion":1095,"start":3149,"conditions":3189,"interventions":3190},[89],[2426],[3137,3152,3153,3154],{"trials":3192,"activeCount":100},[],{"trials":3194,"activeCount":100},[],{"trials":3196,"activeCount":100},[],{"intervention":3154,"totalTrials":135,"cells":3198},{"EARLY_PHASE1":3199,"PHASE1":3201,"PHASE2":3203,"PHASE3":3209,"PHASE4":3211,"NA":3213},{"trials":3200,"activeCount":100},[],{"trials":3202,"activeCount":100},[],{"trials":3204,"activeCount":100},[3205],{"nctId":3146,"briefTitle":3147,"status":192,"phases":3206,"completion":1095,"start":3149,"conditions":3207,"interventions":3208},[89],[2426],[3137,3152,3153,3154],{"trials":3210,"activeCount":100},[],{"trials":3212,"activeCount":100},[],{"trials":3214,"activeCount":100},[],{"intervention":3216,"totalTrials":135,"cells":3217},"Rituximab + CHOP chemotherapy",{"EARLY_PHASE1":3218,"PHASE1":3220,"PHASE2":3222,"PHASE3":3233,"PHASE4":3235,"NA":3237},{"trials":3219,"activeCount":100},[],{"trials":3221,"activeCount":100},[],{"trials":3223,"activeCount":100},[3224],{"nctId":3225,"briefTitle":3226,"status":192,"phases":3227,"primaryCompletion":3228,"completion":3228,"start":3229,"enrollment":9,"conditions":3230,"interventions":3232},"NCT00204659","Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma",[89],"2008-09","2003-03",[3231],"Primary Gastric Diffuse-Large B-Cell Lymphoma",[3216],{"trials":3234,"activeCount":100},[],{"trials":3236,"activeCount":100},[],{"trials":3238,"activeCount":100},[],{"intervention":3240,"totalTrials":135,"cells":3241},"Medical oxygen",{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3246,"PHASE3":3259,"PHASE4":3261,"NA":3263},{"trials":3243,"activeCount":100},[],{"trials":3245,"activeCount":100},[],{"trials":3247,"activeCount":100},[3248],{"nctId":3249,"briefTitle":3250,"status":1093,"phases":3251,"primaryCompletion":3252,"completion":3253,"start":3254,"enrollment":3255,"conditions":3256,"interventions":3258},"NCT03500939","Penumbral Rescue by Normobaric O2 Administration in Patients With Ischemic Stroke and Target Mismatch ProFile",[89],"2022-05-16","2022-08-22","2019-08-01",223,[3257],"Acute Ischemic Stroke",[3240],{"trials":3260,"activeCount":100},[],{"trials":3262,"activeCount":100},[],{"trials":3264,"activeCount":100},[],{"intervention":2355,"totalTrials":135,"cells":3266},{"EARLY_PHASE1":3267,"PHASE1":3269,"PHASE2":3271,"PHASE3":3277,"PHASE4":3279,"NA":3281},{"trials":3268,"activeCount":100},[],{"trials":3270,"activeCount":100},[],{"trials":3272,"activeCount":100},[3273],{"nctId":2349,"briefTitle":2350,"status":192,"phases":3274,"completion":2352,"start":1643,"enrollment":566,"conditions":3275,"interventions":3276},[88,89],[32],[1048,2355],{"trials":3278,"activeCount":100},[],{"trials":3280,"activeCount":100},[],{"trials":3282,"activeCount":100},[],{"intervention":3284,"totalTrials":135,"cells":3285},"Radioimmunotherapy",{"EARLY_PHASE1":3286,"PHASE1":3288,"PHASE2":3290,"PHASE3":3299,"PHASE4":3301,"NA":3303},{"trials":3287,"activeCount":100},[],{"trials":3289,"activeCount":100},[],{"trials":3291,"activeCount":100},[3292],{"nctId":3293,"briefTitle":3294,"status":192,"phases":3295,"completion":3296,"start":1096,"enrollment":228,"conditions":3297,"interventions":3298},"NCT00302757","Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma",[88,89],"2011-07",[2452],[3284],{"trials":3300,"activeCount":100},[],{"trials":3302,"activeCount":100},[],{"trials":3304,"activeCount":100},[],{"intervention":3306,"totalTrials":135,"cells":3307},"MSC",{"EARLY_PHASE1":3308,"PHASE1":3310,"PHASE2":3312,"PHASE3":3324,"PHASE4":3326,"NA":3328},{"trials":3309,"activeCount":100},[],{"trials":3311,"activeCount":100},[],{"trials":3313,"activeCount":100},[3314],{"nctId":3315,"briefTitle":3316,"status":834,"phases":3317,"primaryCompletion":3318,"completion":3319,"start":3320,"enrollment":2186,"conditions":3321,"interventions":3323},"NCT04377334","Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)",[89],"2022-11","2023-02","2022-05",[3322,29],"ARDS",[3306],{"trials":3325,"activeCount":100},[],{"trials":3327,"activeCount":100},[],{"trials":3329,"activeCount":100},[],{"intervention":3331,"totalTrials":135,"cells":3332},"Darbepoetin alfa",{"EARLY_PHASE1":3333,"PHASE1":3335,"PHASE2":3337,"PHASE3":3348,"PHASE4":3350,"NA":3352},{"trials":3334,"activeCount":100},[],{"trials":3336,"activeCount":100},[],{"trials":3338,"activeCount":100},[3339],{"nctId":3340,"briefTitle":3341,"status":192,"phases":3342,"primaryCompletion":2447,"completion":2447,"start":3343,"enrollment":3344,"conditions":3345,"interventions":3347},"NCT00204633","Darbepoetin Alfa in Patients With \"Poor Prognosis\" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)",[89],"2003-07",108,[3346],"Dysgerminoma",[3331],{"trials":3349,"activeCount":100},[],{"trials":3351,"activeCount":100},[],{"trials":3353,"activeCount":100},[],{"intervention":3355,"totalTrials":135,"cells":3356},"Imnovid",{"EARLY_PHASE1":3357,"PHASE1":3359,"PHASE2":3361,"PHASE3":3375,"PHASE4":3377,"NA":3379},{"trials":3358,"activeCount":100},[],{"trials":3360,"activeCount":100},[],{"trials":3362,"activeCount":100},[3363],{"nctId":3364,"briefTitle":3365,"status":192,"phases":3366,"primaryCompletion":3367,"completion":3368,"start":3369,"enrollment":228,"conditions":3370,"interventions":3372},"NCT02046915","Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide",[89],"2016-08-17","2017-08-17","2014-04",[3371],"Relapsed or Refractory Multiple Myeloma",[3355,3373,3374],"Dexamethasone","Endoxan",{"trials":3376,"activeCount":100},[],{"trials":3378,"activeCount":100},[],{"trials":3380,"activeCount":100},[],{"intervention":3373,"totalTrials":135,"cells":3382},{"EARLY_PHASE1":3383,"PHASE1":3385,"PHASE2":3387,"PHASE3":3393,"PHASE4":3395,"NA":3397},{"trials":3384,"activeCount":100},[],{"trials":3386,"activeCount":100},[],{"trials":3388,"activeCount":100},[3389],{"nctId":3364,"briefTitle":3365,"status":192,"phases":3390,"primaryCompletion":3367,"completion":3368,"start":3369,"enrollment":228,"conditions":3391,"interventions":3392},[89],[3371],[3355,3373,3374],{"trials":3394,"activeCount":100},[],{"trials":3396,"activeCount":100},[],{"trials":3398,"activeCount":100},[],{"intervention":3374,"totalTrials":135,"cells":3400},{"EARLY_PHASE1":3401,"PHASE1":3403,"PHASE2":3405,"PHASE3":3411,"PHASE4":3413,"NA":3415},{"trials":3402,"activeCount":100},[],{"trials":3404,"activeCount":100},[],{"trials":3406,"activeCount":100},[3407],{"nctId":3364,"briefTitle":3365,"status":192,"phases":3408,"primaryCompletion":3367,"completion":3368,"start":3369,"enrollment":228,"conditions":3409,"interventions":3410},[89],[3371],[3355,3373,3374],{"trials":3412,"activeCount":100},[],{"trials":3414,"activeCount":100},[],{"trials":3416,"activeCount":100},[],{"intervention":3418,"totalTrials":135,"cells":3419},"Amantadine",{"EARLY_PHASE1":3420,"PHASE1":3422,"PHASE2":3424,"PHASE3":3436,"PHASE4":3438,"NA":3440},{"trials":3421,"activeCount":100},[],{"trials":3423,"activeCount":100},[],{"trials":3425,"activeCount":100},[3426],{"nctId":3427,"briefTitle":3428,"status":834,"phases":3429,"primaryCompletion":3430,"completion":3431,"start":3432,"enrollment":827,"conditions":3433,"interventions":3435},"NCT05479032","Amantadine for Neuroenhancement in Acute Patients Study",[89],"2024-10-30","2024-12-31","2023-03-01",[3434],"Disorder of Consciousness",[3418],{"trials":3437,"activeCount":100},[],{"trials":3439,"activeCount":100},[],{"trials":3441,"activeCount":100},[],{"intervention":3443,"totalTrials":135,"cells":3444},"Buparlisib",{"EARLY_PHASE1":3445,"PHASE1":3447,"PHASE2":3449,"PHASE3":3460,"PHASE4":3462,"NA":3464},{"trials":3446,"activeCount":100},[],{"trials":3448,"activeCount":100},[],{"trials":3450,"activeCount":100},[3451],{"nctId":3452,"briefTitle":3453,"status":834,"phases":3454,"primaryCompletion":2212,"completion":2850,"start":3455,"enrollment":3456,"conditions":3457,"interventions":3459},"NCT02452294","Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)",[89],"2015-07",22,[32,3458],"Metastases",[3443],{"trials":3461,"activeCount":100},[],{"trials":3463,"activeCount":100},[],{"trials":3465,"activeCount":100},[],{"intervention":1049,"totalTrials":135,"cells":3467},{"EARLY_PHASE1":3468,"PHASE1":3470,"PHASE2":3472,"PHASE3":3478,"PHASE4":3480,"NA":3482},{"trials":3469,"activeCount":100},[],{"trials":3471,"activeCount":100},[],{"trials":3473,"activeCount":100},[3474],{"nctId":1037,"briefTitle":1038,"status":834,"phases":3475,"primaryCompletion":1040,"completion":1040,"start":1041,"enrollment":775,"conditions":3476,"interventions":3477},[88,89],[1043],[1045,1046,1047,1027,1048,1049],{"trials":3479,"activeCount":100},[],{"trials":3481,"activeCount":100},[],{"trials":3483,"activeCount":100},[],{"intervention":2306,"totalTrials":135,"cells":3485},{"EARLY_PHASE1":3486,"PHASE1":3488,"PHASE2":3490,"PHASE3":3496,"PHASE4":3498,"NA":3500},{"trials":3487,"activeCount":100},[],{"trials":3489,"activeCount":100},[],{"trials":3491,"activeCount":100},[3492],{"nctId":2298,"briefTitle":2299,"status":1093,"phases":3493,"primaryCompletion":2301,"completion":2301,"start":2302,"enrollment":2303,"conditions":3494,"interventions":3495},[89],[32],[2279,2306,2307],{"trials":3497,"activeCount":100},[],{"trials":3499,"activeCount":100},[],{"trials":3501,"activeCount":100},[],{"intervention":2307,"totalTrials":135,"cells":3503},{"EARLY_PHASE1":3504,"PHASE1":3506,"PHASE2":3508,"PHASE3":3514,"PHASE4":3516,"NA":3518},{"trials":3505,"activeCount":100},[],{"trials":3507,"activeCount":100},[],{"trials":3509,"activeCount":100},[3510],{"nctId":2298,"briefTitle":2299,"status":1093,"phases":3511,"primaryCompletion":2301,"completion":2301,"start":2302,"enrollment":2303,"conditions":3512,"interventions":3513},[89],[32],[2279,2306,2307],{"trials":3515,"activeCount":100},[],{"trials":3517,"activeCount":100},[],{"trials":3519,"activeCount":100},[],{"intervention":3521,"totalTrials":135,"cells":3522},"Multipeptide Vaccine+ XS15",{"EARLY_PHASE1":3523,"PHASE1":3525,"PHASE2":3536,"PHASE3":3538,"PHASE4":3540,"NA":3542},{"trials":3524,"activeCount":100},[],{"trials":3526,"activeCount":100},[3527],{"nctId":3528,"briefTitle":3529,"status":192,"phases":3530,"primaryCompletion":3531,"completion":3531,"start":3532,"enrollment":566,"conditions":3533,"interventions":3535},"NCT04688385","Personalized Multi-peptide Vaccination in CLL Patients",[88],"2024-10-17","2020-12-23",[3534],"Chronic Lymphocytic Leukemia",[3521],{"trials":3537,"activeCount":100},[],{"trials":3539,"activeCount":100},[],{"trials":3541,"activeCount":100},[],{"trials":3543,"activeCount":100},[],{"intervention":3545,"totalTrials":135,"cells":3546},"Nitric oxide, Carbon monoxide, Helium",{"EARLY_PHASE1":3547,"PHASE1":3549,"PHASE2":3560,"PHASE3":3562,"PHASE4":3564,"NA":3566},{"trials":3548,"activeCount":100},[],{"trials":3550,"activeCount":100},[3551],{"nctId":3552,"briefTitle":3553,"status":834,"phases":3554,"completion":3555,"start":1667,"enrollment":3556,"conditions":3557,"interventions":3559},"NCT00315965","Development of a New Method for Steady-State Measurement of NO Lung Diffusing Capacity in Healthy Subjects",[88],"2007-09",107,[3558],"Pulmonary Diffusing Capacity",[3545],{"trials":3561,"activeCount":100},[],{"trials":3563,"activeCount":100},[],{"trials":3565,"activeCount":100},[],{"trials":3567,"activeCount":100},[],{"intervention":199,"totalTrials":135,"cells":3569},{"EARLY_PHASE1":3570,"PHASE1":3572,"PHASE2":3578,"PHASE3":3580,"PHASE4":3582,"NA":3584},{"trials":3571,"activeCount":100},[],{"trials":3573,"activeCount":100},[3574],{"nctId":190,"briefTitle":191,"status":192,"phases":3575,"primaryCompletion":194,"completion":194,"start":195,"enrollment":9,"conditions":3576,"interventions":3577},[88],[197],[199,183],{"trials":3579,"activeCount":100},[],{"trials":3581,"activeCount":100},[],{"trials":3583,"activeCount":100},[],{"trials":3585,"activeCount":100},[],{"intervention":3587,"totalTrials":135,"cells":3588},"multipeptide cocktail",{"EARLY_PHASE1":3589,"PHASE1":3591,"PHASE2":3603,"PHASE3":3605,"PHASE4":3607,"NA":3609},{"trials":3590,"activeCount":100},[],{"trials":3592,"activeCount":100},[3593],{"nctId":3594,"briefTitle":3595,"status":192,"phases":3596,"primaryCompletion":3597,"completion":3598,"start":3599,"enrollment":775,"conditions":3600,"interventions":3602},"NCT04546841","Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults",[88],"2021-09-30","2021-12-02","2020-11-27",[3601],"COVID-19 Vaccine",[3587],{"trials":3604,"activeCount":100},[],{"trials":3606,"activeCount":100},[],{"trials":3608,"activeCount":100},[],{"trials":3610,"activeCount":100},[],{"intervention":3612,"totalTrials":135,"cells":3613},"Multipeptide plus XS15",{"EARLY_PHASE1":3614,"PHASE1":3616,"PHASE2":3627,"PHASE3":3629,"PHASE4":3631,"NA":3633},{"trials":3615,"activeCount":100},[],{"trials":3617,"activeCount":100},[3618],{"nctId":3619,"briefTitle":3620,"status":192,"phases":3621,"primaryCompletion":3622,"completion":3622,"start":3623,"enrollment":2268,"conditions":3624,"interventions":3626},"NCT04842513","Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma",[88],"2024-07-31","2021-05-03",[3625],"Glioblastoma Multiforme of Brain",[3612],{"trials":3628,"activeCount":100},[],{"trials":3630,"activeCount":100},[],{"trials":3632,"activeCount":100},[],{"trials":3634,"activeCount":100},[],{"intervention":3636,"totalTrials":135,"cells":3637},"Mesenchymal Stem Cells",{"EARLY_PHASE1":3638,"PHASE1":3640,"PHASE2":3651,"PHASE3":3653,"PHASE4":3655,"NA":3657},{"trials":3639,"activeCount":100},[],{"trials":3641,"activeCount":100},[3642],{"nctId":3643,"briefTitle":3644,"status":834,"phases":3645,"primaryCompletion":1900,"completion":3646,"start":3647,"enrollment":30,"conditions":3648,"interventions":3650},"NCT02957552","Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver Transplantation",[88],"2021-12","2017-03-10",[3649],"Pediatric Liver Transplantation",[3636],{"trials":3652,"activeCount":100},[],{"trials":3654,"activeCount":100},[],{"trials":3656,"activeCount":100},[],{"trials":3658,"activeCount":100},[],{"intervention":3660,"totalTrials":135,"cells":3661},"KS24.22 cells",{"EARLY_PHASE1":3662,"PHASE1":3664,"PHASE2":3675,"PHASE3":3677,"PHASE4":3679,"NA":3681},{"trials":3663,"activeCount":100},[],{"trials":3665,"activeCount":100},[3666],{"nctId":3667,"briefTitle":3668,"status":192,"phases":3669,"primaryCompletion":3670,"completion":3671,"start":2423,"enrollment":2268,"conditions":3672,"interventions":3674},"NCT01127074","Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422)",[88],"2008-07","2010-01",[3673],"Metastatic Breast Cancer",[3660],{"trials":3676,"activeCount":100},[],{"trials":3678,"activeCount":100},[],{"trials":3680,"activeCount":100},[],{"trials":3682,"activeCount":100},[],{"intervention":3684,"totalTrials":135,"cells":3685},"Everolimus",{"EARLY_PHASE1":3686,"PHASE1":3688,"PHASE2":3700,"PHASE3":3702,"PHASE4":3704,"NA":3706},{"trials":3687,"activeCount":100},[],{"trials":3689,"activeCount":100},[3690],{"nctId":3691,"briefTitle":3692,"status":1093,"phases":3693,"completion":3694,"start":3695,"enrollment":3696,"conditions":3697,"interventions":3699},"NCT00373815","Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease",[88],"2009-10","2006-09",10,[3698],"Graft Versus Host Disease",[3684],{"trials":3701,"activeCount":100},[],{"trials":3703,"activeCount":100},[],{"trials":3705,"activeCount":100},[],{"trials":3707,"activeCount":100},[],{"intervention":3709,"totalTrials":135,"cells":3710},"PAMVAC",{"EARLY_PHASE1":3711,"PHASE1":3713,"PHASE2":3727,"PHASE3":3729,"PHASE4":3731,"NA":3733},{"trials":3712,"activeCount":100},[],{"trials":3714,"activeCount":100},[3715],{"nctId":3716,"briefTitle":3717,"status":192,"phases":3718,"primaryCompletion":3719,"completion":3719,"start":3720,"enrollment":1858,"conditions":3721,"interventions":3723},"NCT02647489","Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted",[88],"2017-11-10","2016-05",[3722],"Malaria, Antepartum",[3709,3724,3725,3726],"Alhydrogel","GLA-SE","GLA-LSQ",{"trials":3728,"activeCount":100},[],{"trials":3730,"activeCount":100},[],{"trials":3732,"activeCount":100},[],{"trials":3734,"activeCount":100},[],{"intervention":3724,"totalTrials":135,"cells":3736},{"EARLY_PHASE1":3737,"PHASE1":3739,"PHASE2":3745,"PHASE3":3747,"PHASE4":3749,"NA":3751},{"trials":3738,"activeCount":100},[],{"trials":3740,"activeCount":100},[3741],{"nctId":3716,"briefTitle":3717,"status":192,"phases":3742,"primaryCompletion":3719,"completion":3719,"start":3720,"enrollment":1858,"conditions":3743,"interventions":3744},[88],[3722],[3709,3724,3725,3726],{"trials":3746,"activeCount":100},[],{"trials":3748,"activeCount":100},[],{"trials":3750,"activeCount":100},[],{"trials":3752,"activeCount":100},[],{"intervention":3725,"totalTrials":135,"cells":3754},{"EARLY_PHASE1":3755,"PHASE1":3757,"PHASE2":3763,"PHASE3":3765,"PHASE4":3767,"NA":3769},{"trials":3756,"activeCount":100},[],{"trials":3758,"activeCount":100},[3759],{"nctId":3716,"briefTitle":3717,"status":192,"phases":3760,"primaryCompletion":3719,"completion":3719,"start":3720,"enrollment":1858,"conditions":3761,"interventions":3762},[88],[3722],[3709,3724,3725,3726],{"trials":3764,"activeCount":100},[],{"trials":3766,"activeCount":100},[],{"trials":3768,"activeCount":100},[],{"trials":3770,"activeCount":100},[],{"intervention":3726,"totalTrials":135,"cells":3772},{"EARLY_PHASE1":3773,"PHASE1":3775,"PHASE2":3781,"PHASE3":3783,"PHASE4":3785,"NA":3787},{"trials":3774,"activeCount":100},[],{"trials":3776,"activeCount":100},[3777],{"nctId":3716,"briefTitle":3717,"status":192,"phases":3778,"primaryCompletion":3719,"completion":3719,"start":3720,"enrollment":1858,"conditions":3779,"interventions":3780},[88],[3722],[3709,3724,3725,3726],{"trials":3782,"activeCount":100},[],{"trials":3784,"activeCount":100},[],{"trials":3786,"activeCount":100},[],{"trials":3788,"activeCount":100},[],{"intervention":3790,"totalTrials":135,"cells":3791},"Oleylphosphocholine",{"EARLY_PHASE1":3792,"PHASE1":3794,"PHASE2":3805,"PHASE3":3807,"PHASE4":3809,"NA":3811},{"trials":3793,"activeCount":100},[],{"trials":3795,"activeCount":100},[3796],{"nctId":3797,"briefTitle":3798,"status":1093,"phases":3799,"primaryCompletion":3800,"completion":3800,"start":3801,"enrollment":19,"conditions":3802,"interventions":3804},"NCT06124144","Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults",[88],"2024-02-27","2023-06-21",[3803],"Leishmaniasis",[3790],{"trials":3806,"activeCount":100},[],{"trials":3808,"activeCount":100},[],{"trials":3810,"activeCount":100},[],{"trials":3812,"activeCount":100},[],{"intervention":3814,"totalTrials":1233,"cells":3815},"human insulin",{"EARLY_PHASE1":3816,"PHASE1":3818,"PHASE2":3820,"PHASE3":3822,"PHASE4":3824,"NA":3826},{"trials":3817,"activeCount":100},[],{"trials":3819,"activeCount":100},[],{"trials":3821,"activeCount":100},[],{"trials":3823,"activeCount":100},[],{"trials":3825,"activeCount":100},[],{"trials":3827,"activeCount":100},[3828,3838,3847,3855],{"nctId":3829,"briefTitle":3830,"status":834,"phases":3831,"primaryCompletion":3832,"start":2474,"enrollment":2631,"conditions":3833,"interventions":3835},"NCT00638209","Insulin Sensitivity of the Brain in Pathogenesis of Diabetes Mellitus Type 2",[92],"2010-05",[3834],"Human Physiology of Energy Homeostasis",[3836,3837],"Human insulin","Saline",{"nctId":3839,"briefTitle":3840,"status":192,"phases":3841,"primaryCompletion":3842,"completion":3843,"start":3844,"enrollment":3456,"conditions":3845,"interventions":3846},"NCT03651661","Pupillography as Screening Tool for Brain Insulin Resistance",[92],"2018-11-01","2019-01-07","2018-07-03",[15],[3814],{"nctId":3848,"briefTitle":3849,"status":192,"phases":3850,"primaryCompletion":1969,"completion":1969,"start":3851,"enrollment":3852,"conditions":3853,"interventions":3854},"NCT02468999","Influence of Central Nervous Insulin Action on Insulin Sensitivity of Peripheral Organs in Lean Versus Overweight Humans",[92],"2015-01",21,[18],[3814],{"nctId":3856,"briefTitle":3857,"status":192,"phases":3858,"primaryCompletion":3369,"completion":3369,"start":3859,"enrollment":3860,"conditions":3861,"interventions":3862},"NCT01797601","Insulin Sensitivity of the Human CNS System: fMRI Study With Intranasal Insulin Application",[92],"2013-02",48,[15,1860],[3863],"Human Insulin",{"intervention":3865,"totalTrials":1028,"cells":3866},"Meropenem",{"EARLY_PHASE1":3867,"PHASE1":3869,"PHASE2":3871,"PHASE3":3873,"PHASE4":3875,"NA":3877},{"trials":3868,"activeCount":100},[],{"trials":3870,"activeCount":100},[],{"trials":3872,"activeCount":100},[],{"trials":3874,"activeCount":100},[],{"trials":3876,"activeCount":100},[],{"trials":3878,"activeCount":100},[3879,3889,3902],{"nctId":3880,"briefTitle":3881,"status":192,"phases":3882,"primaryCompletion":3883,"completion":3883,"start":3884,"enrollment":228,"conditions":3885,"interventions":3887},"NCT03140826","Amplification and Selection of Antimicrobial Resistance in the Intestine II",[],"2020-07-31","2018-01-30",[3886],"Antibiotic Selection Pressure",[3888],"meropenem",{"nctId":3890,"briefTitle":3891,"status":1093,"phases":3892,"completion":1857,"start":2826,"enrollment":2186,"conditions":3893,"interventions":3896},"NCT00435305","Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion",[],[3894,3895],"Pneumonia","Bacteremia",[3865,3897,3898,3899,3900,3901],"Vancomycin","Linezolid","Piperacillin\u002FTazobactam","Cefepim","Ceftazidim",{"nctId":3903,"briefTitle":3904,"status":126,"phases":3905,"primaryCompletion":3906,"completion":3646,"start":3907,"enrollment":100,"conditions":3908,"interventions":3911},"NCT03036826","Computer-based Dosage Calculation for Antibiotics",[],"2021-06","2019-06",[3909,3910],"Acute Kidney Insufficiency","Anti-Infective Agent Toxicity",[3912,3865],"Piperacillin\u002Ftazobactam",{"intervention":3837,"totalTrials":96,"cells":3914},{"EARLY_PHASE1":3915,"PHASE1":3917,"PHASE2":3919,"PHASE3":3921,"PHASE4":3923,"NA":3925},{"trials":3916,"activeCount":100},[],{"trials":3918,"activeCount":100},[],{"trials":3920,"activeCount":100},[],{"trials":3922,"activeCount":100},[],{"trials":3924,"activeCount":100},[],{"trials":3926,"activeCount":100},[3927,3931],{"nctId":3829,"briefTitle":3830,"status":834,"phases":3928,"primaryCompletion":3832,"start":2474,"enrollment":2631,"conditions":3929,"interventions":3930},[92],[3834],[3836,3837],{"nctId":3932,"briefTitle":3933,"status":192,"phases":3934,"primaryCompletion":3935,"completion":3935,"start":3936,"enrollment":3937,"conditions":3938,"interventions":3939},"NCT06576440","Effects of Ghrelin Administration on Motivation",[92],"2024-12-20","2024-09-02",24,[24],[3940,3837],"Ghrelin",{"intervention":3940,"totalTrials":96,"cells":3942},{"EARLY_PHASE1":3943,"PHASE1":3945,"PHASE2":3947,"PHASE3":3957,"PHASE4":3959,"NA":3961},{"trials":3944,"activeCount":100},[],{"trials":3946,"activeCount":100},[],{"trials":3948,"activeCount":100},[3949],{"nctId":3950,"briefTitle":3951,"status":192,"phases":3952,"primaryCompletion":3953,"completion":3953,"start":3954,"enrollment":1456,"conditions":3955,"interventions":3956},"NCT05318924","Effects of Ghrelin Administration on Dopamine and Effort",[88,89],"2024-08-06","2022-02-21",[24],[3940],{"trials":3958,"activeCount":100},[],{"trials":3960,"activeCount":100},[],{"trials":3962,"activeCount":100},[3963],{"nctId":3932,"briefTitle":3933,"status":192,"phases":3964,"primaryCompletion":3935,"completion":3935,"start":3936,"enrollment":3937,"conditions":3965,"interventions":3966},[92],[24],[3940,3837],{"intervention":3968,"totalTrials":96,"cells":3969},"intranasal insulin",{"EARLY_PHASE1":3970,"PHASE1":3972,"PHASE2":3974,"PHASE3":3976,"PHASE4":3978,"NA":3980},{"trials":3971,"activeCount":100},[],{"trials":3973,"activeCount":100},[],{"trials":3975,"activeCount":100},[],{"trials":3977,"activeCount":100},[],{"trials":3979,"activeCount":100},[],{"trials":3981,"activeCount":100},[3982,3993],{"nctId":3983,"briefTitle":3984,"status":192,"phases":3985,"primaryCompletion":3986,"completion":3987,"start":3988,"enrollment":3989,"conditions":3990,"interventions":3992},"NCT03929419","\"Effect of Central Insulin Administration on Whole-body Insulin Sensitivity in Women\"",[92],"2021-03-25","2021-04-30","2019-04-21",29,[3991],"Insulin Sensitivity",[3968],{"nctId":3994,"briefTitle":3995,"status":192,"phases":3996,"primaryCompletion":3997,"completion":3998,"start":3999,"enrollment":2268,"conditions":4000,"interventions":4002},"NCT02870361","Influence of Central Nervous Insulin Sensitivity on Insulin Secretion",[92],"2018-02","2018-04","2016-08",[4001],"Insulin Secretion",[3968],{"intervention":3897,"totalTrials":96,"cells":4004},{"EARLY_PHASE1":4005,"PHASE1":4007,"PHASE2":4009,"PHASE3":4011,"PHASE4":4013,"NA":4015},{"trials":4006,"activeCount":100},[],{"trials":4008,"activeCount":100},[],{"trials":4010,"activeCount":100},[],{"trials":4012,"activeCount":100},[],{"trials":4014,"activeCount":100},[],{"trials":4016,"activeCount":100},[4017,4021],{"nctId":3890,"briefTitle":3891,"status":1093,"phases":4018,"completion":1857,"start":2826,"enrollment":2186,"conditions":4019,"interventions":4020},[],[3894,3895],[3865,3897,3898,3899,3900,3901],{"nctId":4022,"briefTitle":4023,"status":834,"phases":4024,"primaryCompletion":1717,"completion":1692,"start":1833,"enrollment":9,"conditions":4025,"interventions":4028},"NCT01942447","Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis",[92],[4026,4027],"Clostridium Difficile","Clostridium Difficile Infection",[4029,3897],"FMT",{"intervention":3899,"totalTrials":96,"cells":4031},{"EARLY_PHASE1":4032,"PHASE1":4034,"PHASE2":4036,"PHASE3":4038,"PHASE4":4040,"NA":4042},{"trials":4033,"activeCount":100},[],{"trials":4035,"activeCount":100},[],{"trials":4037,"activeCount":100},[],{"trials":4039,"activeCount":100},[],{"trials":4041,"activeCount":100},[],{"trials":4043,"activeCount":100},[4044,4048],{"nctId":3890,"briefTitle":3891,"status":1093,"phases":4045,"completion":1857,"start":2826,"enrollment":2186,"conditions":4046,"interventions":4047},[],[3894,3895],[3865,3897,3898,3899,3900,3901],{"nctId":3903,"briefTitle":3904,"status":126,"phases":4049,"primaryCompletion":3906,"completion":3646,"start":3907,"enrollment":100,"conditions":4050,"interventions":4051},[],[3909,3910],[3912,3865],{"intervention":4053,"totalTrials":96,"cells":4054},"ABT",{"EARLY_PHASE1":4055,"PHASE1":4057,"PHASE2":4059,"PHASE3":4061,"PHASE4":4063,"NA":4065},{"trials":4056,"activeCount":100},[],{"trials":4058,"activeCount":100},[],{"trials":4060,"activeCount":100},[],{"trials":4062,"activeCount":100},[],{"trials":4064,"activeCount":100},[],{"trials":4066,"activeCount":100},[4067,4077],{"nctId":4068,"briefTitle":4069,"status":834,"phases":4070,"primaryCompletion":4071,"completion":4071,"start":4072,"enrollment":4073,"conditions":4074,"interventions":4076},"NCT05563753","Early Antibiotic Therapy and Vaccinations in Preterm Infants",[],"2024-09","2022-09-01",82,[4075],"Vaccination Reaction",[4053],{"nctId":4078,"briefTitle":4079,"status":834,"phases":4080,"primaryCompletion":4081,"completion":4081,"start":4082,"enrollment":566,"conditions":4083,"interventions":4084},"NCT04109833","Early Antibiotic Therapy and Vaccination",[],"2021-10","2019-09-27",[4075],[4053],{"intervention":4086,"totalTrials":135,"cells":4087},"Whole Genome Analysis",{"EARLY_PHASE1":4088,"PHASE1":4090,"PHASE2":4092,"PHASE3":4094,"PHASE4":4096,"NA":4098},{"trials":4089,"activeCount":100},[],{"trials":4091,"activeCount":100},[],{"trials":4093,"activeCount":100},[],{"trials":4095,"activeCount":100},[],{"trials":4097,"activeCount":100},[],{"trials":4099,"activeCount":100},[4100],{"nctId":4101,"briefTitle":4102,"status":192,"phases":4103,"primaryCompletion":3125,"completion":4104,"start":4105,"enrollment":4106,"conditions":4107,"interventions":4108},"NCT04364828","NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression",[92],"2023-08-31","2020-10-21",1000,[29],[4086,4109,4110],"T-cell receptor (TCR) repertoire","SARS-CoV-2 viral composition",{"intervention":4109,"totalTrials":135,"cells":4112},{"EARLY_PHASE1":4113,"PHASE1":4115,"PHASE2":4117,"PHASE3":4119,"PHASE4":4121,"NA":4123},{"trials":4114,"activeCount":100},[],{"trials":4116,"activeCount":100},[],{"trials":4118,"activeCount":100},[],{"trials":4120,"activeCount":100},[],{"trials":4122,"activeCount":100},[],{"trials":4124,"activeCount":100},[4125],{"nctId":4101,"briefTitle":4102,"status":192,"phases":4126,"primaryCompletion":3125,"completion":4104,"start":4105,"enrollment":4106,"conditions":4127,"interventions":4128},[92],[29],[4086,4109,4110],{"intervention":4110,"totalTrials":135,"cells":4130},{"EARLY_PHASE1":4131,"PHASE1":4133,"PHASE2":4135,"PHASE3":4137,"PHASE4":4139,"NA":4141},{"trials":4132,"activeCount":100},[],{"trials":4134,"activeCount":100},[],{"trials":4136,"activeCount":100},[],{"trials":4138,"activeCount":100},[],{"trials":4140,"activeCount":100},[],{"trials":4142,"activeCount":100},[4143],{"nctId":4101,"briefTitle":4102,"status":192,"phases":4144,"primaryCompletion":3125,"completion":4104,"start":4105,"enrollment":4106,"conditions":4145,"interventions":4146},[92],[29],[4086,4109,4110],{"intervention":4148,"totalTrials":135,"cells":4149},"Personalized multi-peptide vaccine",{"EARLY_PHASE1":4150,"PHASE1":4152,"PHASE2":4154,"PHASE3":4156,"PHASE4":4158,"NA":4160},{"trials":4151,"activeCount":100},[],{"trials":4153,"activeCount":100},[],{"trials":4155,"activeCount":100},[],{"trials":4157,"activeCount":100},[],{"trials":4159,"activeCount":100},[],{"trials":4161,"activeCount":100},[4162],{"nctId":4163,"briefTitle":4164,"status":4165,"phases":4166,"conditions":4167,"interventions":4168},"NCT05014607","Personalized Multi-peptide Vaccination in Combination With the TLR1\u002F2 Ligand XS15 in Cancer Patients","AVAILABLE",[],[3103],[4148],{"intervention":4170,"totalTrials":135,"cells":4171},"infiltration with triamcinolone and bupivacaine",{"EARLY_PHASE1":4172,"PHASE1":4174,"PHASE2":4176,"PHASE3":4178,"PHASE4":4180,"NA":4182},{"trials":4173,"activeCount":100},[],{"trials":4175,"activeCount":100},[],{"trials":4177,"activeCount":100},[],{"trials":4179,"activeCount":100},[],{"trials":4181,"activeCount":100},[],{"trials":4183,"activeCount":100},[4184],{"nctId":4185,"briefTitle":4186,"status":192,"phases":4187,"primaryCompletion":4188,"completion":4188,"start":4189,"enrollment":827,"conditions":4190,"interventions":4192},"NCT03308149","Predictability of the Effects of Facet Joint Infiltration in the Degenerate Lumbar Spine When Assessing MRI Scans",[],"2017-01-10","2016-01-10",[4191],"Infiltration Facet Joint",[4170],{"intervention":4194,"totalTrials":135,"cells":4195},"Lowering cholesterol concentrations by PCSK-9 inhibitor",{"EARLY_PHASE1":4196,"PHASE1":4198,"PHASE2":4200,"PHASE3":4202,"PHASE4":4204,"NA":4206},{"trials":4197,"activeCount":100},[],{"trials":4199,"activeCount":100},[],{"trials":4201,"activeCount":100},[],{"trials":4203,"activeCount":100},[],{"trials":4205,"activeCount":100},[],{"trials":4207,"activeCount":100},[4208],{"nctId":4209,"briefTitle":4210,"status":1093,"phases":4211,"primaryCompletion":4212,"completion":4212,"start":4213,"enrollment":22,"conditions":4214,"interventions":4216},"NCT04314167","Effect of Serum LDL Cholesterol Concentration on Pancreatic Insulin Secretion",[92],"2024-03-01","2020-07-28",[4215,18,4001],"Hypercholesterolemia",[4194],{"intervention":4218,"totalTrials":135,"cells":4219},"Intravenous glucagon",{"EARLY_PHASE1":4220,"PHASE1":4222,"PHASE2":4224,"PHASE3":4226,"PHASE4":4228,"NA":4230},{"trials":4221,"activeCount":100},[],{"trials":4223,"activeCount":100},[],{"trials":4225,"activeCount":100},[],{"trials":4227,"activeCount":100},[],{"trials":4229,"activeCount":100},[],{"trials":4231,"activeCount":100},[4232],{"nctId":4233,"briefTitle":4234,"status":192,"phases":4235,"primaryCompletion":4236,"completion":4237,"start":4238,"enrollment":3101,"conditions":4239,"interventions":4241},"NCT03061227","Characterization of Metabolic and Brain Effects of Rising Glucagon During an Oral Glucose Challenge",[92],"2019-01-17","2020-04-30","2017-02-10",[4240,1860],"Metabolic Syndrome",[4218,4242],"Intravenous saline",{"intervention":4242,"totalTrials":135,"cells":4244},{"EARLY_PHASE1":4245,"PHASE1":4247,"PHASE2":4249,"PHASE3":4251,"PHASE4":4253,"NA":4255},{"trials":4246,"activeCount":100},[],{"trials":4248,"activeCount":100},[],{"trials":4250,"activeCount":100},[],{"trials":4252,"activeCount":100},[],{"trials":4254,"activeCount":100},[],{"trials":4256,"activeCount":100},[4257],{"nctId":4233,"briefTitle":4234,"status":192,"phases":4258,"primaryCompletion":4236,"completion":4237,"start":4238,"enrollment":3101,"conditions":4259,"interventions":4260},[92],[4240,1860],[4218,4242],{"intervention":4262,"totalTrials":135,"cells":4263},"Daptomycin",{"EARLY_PHASE1":4264,"PHASE1":4266,"PHASE2":4268,"PHASE3":4270,"PHASE4":4272,"NA":4274},{"trials":4265,"activeCount":100},[],{"trials":4267,"activeCount":100},[],{"trials":4269,"activeCount":100},[],{"trials":4271,"activeCount":100},[],{"trials":4273,"activeCount":100},[],{"trials":4275,"activeCount":100},[4276],{"nctId":4277,"briefTitle":4278,"status":192,"phases":4279,"primaryCompletion":4280,"completion":4280,"start":4281,"enrollment":22,"conditions":4282,"interventions":4284},"NCT03004066","Daptomycin Concentration in Drainage Fluid and Blood Samples of ICU Patients",[],"2019-03-31","2016-10",[4283],"Heart Assist Device",[4262],{"intervention":4286,"totalTrials":135,"cells":4287},"Multi-OMICS",{"EARLY_PHASE1":4288,"PHASE1":4290,"PHASE2":4292,"PHASE3":4294,"PHASE4":4296,"NA":4298},{"trials":4289,"activeCount":100},[],{"trials":4291,"activeCount":100},[],{"trials":4293,"activeCount":100},[],{"trials":4295,"activeCount":100},[],{"trials":4297,"activeCount":100},[],{"trials":4299,"activeCount":100},[4300],{"nctId":4301,"briefTitle":4302,"status":834,"phases":4303,"primaryCompletion":4304,"completion":4304,"start":4305,"enrollment":4306,"conditions":4307,"interventions":4308},"NCT04873128","Comparative Genetic and Immune Response Analysis of Different COVID-19 Vaccine Candidates Using Multi-OMICS Approach",[92],"2024-07-01","2021-06-10",110,[35],[4286],{"intervention":4310,"totalTrials":135,"cells":4311},"GLP-1",{"EARLY_PHASE1":4312,"PHASE1":4314,"PHASE2":4316,"PHASE3":4318,"PHASE4":4320,"NA":4322},{"trials":4313,"activeCount":100},[],{"trials":4315,"activeCount":100},[],{"trials":4317,"activeCount":100},[],{"trials":4319,"activeCount":100},[],{"trials":4321,"activeCount":100},[],{"trials":4323,"activeCount":100},[4324],{"nctId":4325,"briefTitle":4326,"status":126,"phases":4327,"primaryCompletion":1302,"completion":2448,"start":4328,"enrollment":100,"conditions":4329,"interventions":4330},"NCT00869102","Characterization of Beta Cell Failure",[92],"2009-05",[1860,4240],[4310],{"intervention":4332,"totalTrials":135,"cells":4333},"Choline Chloride",{"EARLY_PHASE1":4334,"PHASE1":4336,"PHASE2":4338,"PHASE3":4340,"PHASE4":4342,"NA":4344},{"trials":4335,"activeCount":100},[],{"trials":4337,"activeCount":100},[],{"trials":4339,"activeCount":100},[],{"trials":4341,"activeCount":100},[],{"trials":4343,"activeCount":100},[],{"trials":4345,"activeCount":100},[4346],{"nctId":4347,"briefTitle":4348,"status":192,"phases":4349,"primaryCompletion":4350,"completion":4351,"start":4352,"enrollment":3696,"conditions":4353,"interventions":4355},"NCT03312140","Examination of the Lipid Metabolism of the Liver After Choline Substitution in Cystic Fibrosis",[92],"2016-04-24","2017-02-08","2014-11-06",[4354],"Cystic Fibrosis Liver Disease",[4332],{"intervention":4357,"totalTrials":135,"cells":4358},"IgM enriched Immunoglobulins",{"EARLY_PHASE1":4359,"PHASE1":4361,"PHASE2":4363,"PHASE3":4365,"PHASE4":4367,"NA":4369},{"trials":4360,"activeCount":100},[],{"trials":4362,"activeCount":100},[],{"trials":4364,"activeCount":100},[],{"trials":4366,"activeCount":100},[],{"trials":4368,"activeCount":100},[],{"trials":4370,"activeCount":100},[4371],{"nctId":4372,"briefTitle":4373,"status":192,"phases":4374,"primaryCompletion":2852,"completion":3720,"start":4375,"enrollment":4376,"conditions":4377,"interventions":4379},"NCT02961166","Immunglobulin M Enriched Intra Venous Immunoglobulin (IVIG) Therapy in Adult Respiratory Distress Syndrom (ARDS) Patients",[],"2012-01",57,[1928,4378],"Septic Shock",[4357],{"intervention":4381,"totalTrials":135,"cells":4382},"Betamethason Sodium Phosphate",{"EARLY_PHASE1":4383,"PHASE1":4385,"PHASE2":4387,"PHASE3":4389,"PHASE4":4391,"NA":4393},{"trials":4384,"activeCount":100},[],{"trials":4386,"activeCount":100},[],{"trials":4388,"activeCount":100},[],{"trials":4390,"activeCount":100},[],{"trials":4392,"activeCount":100},[],{"trials":4394,"activeCount":100},[4395],{"nctId":4396,"briefTitle":4397,"status":834,"phases":4398,"primaryCompletion":3431,"completion":3431,"start":4399,"enrollment":3937,"conditions":4400,"interventions":4402},"NCT03831126","Stress and Fetal Brain Development",[],"2019-02-01",[4401],"Pregnancy",[4381],{"intervention":4404,"totalTrials":135,"cells":4405},"Sufentanil",{"EARLY_PHASE1":4406,"PHASE1":4408,"PHASE2":4410,"PHASE3":4412,"PHASE4":4414,"NA":4416},{"trials":4407,"activeCount":100},[],{"trials":4409,"activeCount":100},[],{"trials":4411,"activeCount":100},[],{"trials":4413,"activeCount":100},[],{"trials":4415,"activeCount":100},[],{"trials":4417,"activeCount":100},[4418],{"nctId":4419,"briefTitle":4420,"status":834,"phases":4421,"primaryCompletion":4422,"completion":4423,"start":4424,"enrollment":1071,"conditions":4425,"interventions":4428},"NCT03355352","Observational Study of Analgesia and Cost-efficiency of Analgetic Medication Pumps (Zalviso and PCA-syringe Pump (PCA=Patient Controlled Analgesia)) After Urogenital Intervention at the Clinical Daily Routine",[],"2018-08-01","2018-12-01","2017-11-01",[4426,4427],"Analgesic Quality","Mobility",[4404],{"intervention":4430,"totalTrials":135,"cells":4431},"effect of insulin on peptide transport",{"EARLY_PHASE1":4432,"PHASE1":4434,"PHASE2":4436,"PHASE3":4438,"PHASE4":4440,"NA":4442},{"trials":4433,"activeCount":100},[],{"trials":4435,"activeCount":100},[],{"trials":4437,"activeCount":100},[],{"trials":4439,"activeCount":100},[],{"trials":4441,"activeCount":100},[],{"trials":4443,"activeCount":100},[4444],{"nctId":4445,"briefTitle":4446,"status":834,"phases":4447,"primaryCompletion":4448,"completion":4449,"start":4450,"enrollment":9,"conditions":4451,"interventions":4452},"NCT04038086","Transport of Satiety Factors Into the CSF",[92],"2022-12-31","2023-06-01","2019-07-15",[15],[4430],{"intervention":4454,"totalTrials":135,"cells":4455},"human insulin as nasal spray",{"EARLY_PHASE1":4456,"PHASE1":4458,"PHASE2":4460,"PHASE3":4462,"PHASE4":4464,"NA":4466},{"trials":4457,"activeCount":100},[],{"trials":4459,"activeCount":100},[],{"trials":4461,"activeCount":100},[],{"trials":4463,"activeCount":100},[],{"trials":4465,"activeCount":100},[],{"trials":4467,"activeCount":100},[4468],{"nctId":4469,"briefTitle":4470,"status":192,"phases":4471,"primaryCompletion":4472,"start":4473,"enrollment":3696,"conditions":4474,"interventions":4475},"NCT01847456","Influence of Brain Insulin Sensitivity on Peripheral Insulin Sensitivity",[92],"2013-11","2013-04",[3991],[4454],{"intervention":4477,"totalTrials":135,"cells":4478},"5-ALA-guided surgery",{"EARLY_PHASE1":4479,"PHASE1":4481,"PHASE2":4483,"PHASE3":4485,"PHASE4":4487,"NA":4489},{"trials":4480,"activeCount":100},[],{"trials":4482,"activeCount":100},[],{"trials":4484,"activeCount":100},[],{"trials":4486,"activeCount":100},[],{"trials":4488,"activeCount":100},[],{"trials":4490,"activeCount":100},[4491],{"nctId":4492,"briefTitle":4493,"status":192,"phases":4494,"primaryCompletion":4495,"completion":4496,"start":2266,"enrollment":4497,"conditions":4498,"interventions":4500},"NCT02379572","Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas",[92],"2020-06","2021-07-01",315,[4499],"Glioblastoma",[4477],{"intervention":3898,"totalTrials":135,"cells":4502},{"EARLY_PHASE1":4503,"PHASE1":4505,"PHASE2":4507,"PHASE3":4509,"PHASE4":4511,"NA":4513},{"trials":4504,"activeCount":100},[],{"trials":4506,"activeCount":100},[],{"trials":4508,"activeCount":100},[],{"trials":4510,"activeCount":100},[],{"trials":4512,"activeCount":100},[],{"trials":4514,"activeCount":100},[4515],{"nctId":3890,"briefTitle":3891,"status":1093,"phases":4516,"completion":1857,"start":2826,"enrollment":2186,"conditions":4517,"interventions":4518},[],[3894,3895],[3865,3897,3898,3899,3900,3901],{"intervention":3900,"totalTrials":135,"cells":4520},{"EARLY_PHASE1":4521,"PHASE1":4523,"PHASE2":4525,"PHASE3":4527,"PHASE4":4529,"NA":4531},{"trials":4522,"activeCount":100},[],{"trials":4524,"activeCount":100},[],{"trials":4526,"activeCount":100},[],{"trials":4528,"activeCount":100},[],{"trials":4530,"activeCount":100},[],{"trials":4532,"activeCount":100},[4533],{"nctId":3890,"briefTitle":3891,"status":1093,"phases":4534,"completion":1857,"start":2826,"enrollment":2186,"conditions":4535,"interventions":4536},[],[3894,3895],[3865,3897,3898,3899,3900,3901],{"intervention":3901,"totalTrials":135,"cells":4538},{"EARLY_PHASE1":4539,"PHASE1":4541,"PHASE2":4543,"PHASE3":4545,"PHASE4":4547,"NA":4549},{"trials":4540,"activeCount":100},[],{"trials":4542,"activeCount":100},[],{"trials":4544,"activeCount":100},[],{"trials":4546,"activeCount":100},[],{"trials":4548,"activeCount":100},[],{"trials":4550,"activeCount":100},[4551],{"nctId":3890,"briefTitle":3891,"status":1093,"phases":4552,"completion":1857,"start":2826,"enrollment":2186,"conditions":4553,"interventions":4554},[],[3894,3895],[3865,3897,3898,3899,3900,3901],{"intervention":4029,"totalTrials":135,"cells":4556},{"EARLY_PHASE1":4557,"PHASE1":4559,"PHASE2":4561,"PHASE3":4563,"PHASE4":4565,"NA":4567},{"trials":4558,"activeCount":100},[],{"trials":4560,"activeCount":100},[],{"trials":4562,"activeCount":100},[],{"trials":4564,"activeCount":100},[],{"trials":4566,"activeCount":100},[],{"trials":4568,"activeCount":100},[4569],{"nctId":4022,"briefTitle":4023,"status":834,"phases":4570,"primaryCompletion":1717,"completion":1692,"start":1833,"enrollment":9,"conditions":4571,"interventions":4572},[92],[4026,4027],[4029,3897],{"intervention":4574,"totalTrials":135,"cells":4575},"WGS Diagnostic Blood take for genetic diagnostic.",{"EARLY_PHASE1":4576,"PHASE1":4578,"PHASE2":4580,"PHASE3":4582,"PHASE4":4584,"NA":4586},{"trials":4577,"activeCount":100},[],{"trials":4579,"activeCount":100},[],{"trials":4581,"activeCount":100},[],{"trials":4583,"activeCount":100},[],{"trials":4585,"activeCount":100},[],{"trials":4587,"activeCount":100},[4588],{"nctId":4589,"briefTitle":4590,"status":834,"phases":4591,"primaryCompletion":4592,"completion":4593,"start":4594,"enrollment":1071,"conditions":4595,"interventions":4596},"NCT04315727","Identification of the Genetic Causes of Rare Diseases With Negative Exome Findings",[92],"2024-07","2024-12","2021-02-01",[21,829],[4574,4597],"Hair collection",{"intervention":4597,"totalTrials":135,"cells":4599},{"EARLY_PHASE1":4600,"PHASE1":4602,"PHASE2":4604,"PHASE3":4606,"PHASE4":4608,"NA":4610},{"trials":4601,"activeCount":100},[],{"trials":4603,"activeCount":100},[],{"trials":4605,"activeCount":100},[],{"trials":4607,"activeCount":100},[],{"trials":4609,"activeCount":100},[],{"trials":4611,"activeCount":100},[4612],{"nctId":4589,"briefTitle":4590,"status":834,"phases":4613,"primaryCompletion":4592,"completion":4593,"start":4594,"enrollment":1071,"conditions":4614,"interventions":4615},[92],[21,829],[4574,4597],{"intervention":4617,"totalTrials":135,"cells":4618},"recombinant human growth hormone",{"EARLY_PHASE1":4619,"PHASE1":4621,"PHASE2":4623,"PHASE3":4625,"PHASE4":4627,"NA":4629},{"trials":4620,"activeCount":100},[],{"trials":4622,"activeCount":100},[],{"trials":4624,"activeCount":100},[],{"trials":4626,"activeCount":100},[],{"trials":4628,"activeCount":100},[],{"trials":4630,"activeCount":100},[4631],{"nctId":4632,"briefTitle":4633,"status":192,"phases":4634,"primaryCompletion":1428,"completion":4635,"start":2185,"conditions":4636,"interventions":4639},"NCT00443144","D3-GHR Polymorphism and Turner Syndrome",[],"2007-05",[4637,4638],"Turner Syndrome","Short Stature",[4617],{"intervention":4641,"totalTrials":135,"cells":4642},"Bispecific antibodies",{"EARLY_PHASE1":4643,"PHASE1":4645,"PHASE2":4647,"PHASE3":4649,"PHASE4":4651,"NA":4653},{"trials":4644,"activeCount":100},[],{"trials":4646,"activeCount":100},[],{"trials":4648,"activeCount":100},[],{"trials":4650,"activeCount":100},[],{"trials":4652,"activeCount":100},[],{"trials":4654,"activeCount":100},[4655],{"nctId":4656,"briefTitle":4657,"status":4165,"phases":4658,"conditions":4659,"interventions":4660},"NCT05119257","(Bispecific) Antibodies in Cancer Patients",[],[3103],[4641],{"intervention":4662,"totalTrials":135,"cells":4663},"Next Generation Sequencing",{"EARLY_PHASE1":4664,"PHASE1":4666,"PHASE2":4668,"PHASE3":4670,"PHASE4":4672,"NA":4674},{"trials":4665,"activeCount":100},[],{"trials":4667,"activeCount":100},[],{"trials":4669,"activeCount":100},[],{"trials":4671,"activeCount":100},[],{"trials":4673,"activeCount":100},[],{"trials":4675,"activeCount":100},[4676],{"nctId":4677,"briefTitle":4678,"status":192,"phases":4679,"primaryCompletion":4680,"completion":4681,"start":4682,"enrollment":566,"conditions":4683,"interventions":4684},"NCT03962452","Mitochondrial Diseases - Long-read Genome and Transcriptome Sequencing in Cases Unresolved After Short-read Genomics",[92],"2024-02-01","2025-02-01","2019-03-01",[21,35],[4662],{"intervention":4686,"totalTrials":135,"cells":4687},"PIPAC with oxaliplatin",{"EARLY_PHASE1":4688,"PHASE1":4690,"PHASE2":4692,"PHASE3":4694,"PHASE4":4696,"NA":4698},{"trials":4689,"activeCount":100},[],{"trials":4691,"activeCount":100},[],{"trials":4693,"activeCount":100},[],{"trials":4695,"activeCount":100},[],{"trials":4697,"activeCount":100},[],{"trials":4699,"activeCount":100},[4700],{"nctId":4701,"briefTitle":4702,"status":834,"phases":4703,"primaryCompletion":4704,"completion":1054,"start":4705,"enrollment":228,"conditions":4706,"interventions":4709},"NCT04122885","Study of Plasma Tumor-promoting Factors and Immune Function After Laparotomy, Cytoreductive Surgery and HIPEC vs. PIPAC in Patients With Peritoneal Metastasis",[],"2020-09-30","2019-10-01",[4707,4708],"Peritoneal Cancer","Chemotherapy-Induced Change",[4686],{"intervention":4711,"totalTrials":135,"cells":4712},"Levodopa administration",{"EARLY_PHASE1":4713,"PHASE1":4715,"PHASE2":4717,"PHASE3":4719,"PHASE4":4721,"NA":4723},{"trials":4714,"activeCount":100},[],{"trials":4716,"activeCount":100},[],{"trials":4718,"activeCount":100},[],{"trials":4720,"activeCount":100},[],{"trials":4722,"activeCount":100},[],{"trials":4724,"activeCount":100},[4725],{"nctId":4726,"briefTitle":4727,"status":834,"phases":4728,"primaryCompletion":50,"completion":50,"start":4729,"enrollment":4730,"conditions":4731,"interventions":4734},"NCT06365515","Dopamine, Reward Learning and Sex Hormones",[92],"2024-05",90,[4732,4733],"Hormonal Changes","Menstrual Cycle",[4711],{"intervention":4736,"totalTrials":135,"cells":4737},"platelet transfusion",{"EARLY_PHASE1":4738,"PHASE1":4740,"PHASE2":4742,"PHASE3":4744,"PHASE4":4746,"NA":4748},{"trials":4739,"activeCount":100},[],{"trials":4741,"activeCount":100},[],{"trials":4743,"activeCount":100},[],{"trials":4745,"activeCount":100},[],{"trials":4747,"activeCount":100},[],{"trials":4749,"activeCount":100},[4750],{"nctId":4751,"briefTitle":4752,"status":126,"phases":4753,"primaryCompletion":4754,"completion":4755,"start":4756,"enrollment":100,"conditions":4757,"interventions":4760},"NCT03968484","Platelet Transfusion in Sepsis Trial",[92],"2022-08-01","2023-02-01","2020-08-01",[4758,4759],"Sepsis","Thrombocytopenia",[4736],{"intervention":4762,"totalTrials":135,"cells":4763},"WGS-Diagnostic",{"EARLY_PHASE1":4764,"PHASE1":4766,"PHASE2":4768,"PHASE3":4770,"PHASE4":4772,"NA":4774},{"trials":4765,"activeCount":100},[],{"trials":4767,"activeCount":100},[],{"trials":4769,"activeCount":100},[],{"trials":4771,"activeCount":100},[],{"trials":4773,"activeCount":100},[],{"trials":4775,"activeCount":100},[4776],{"nctId":4777,"briefTitle":4778,"status":192,"phases":4779,"primaryCompletion":4780,"completion":4780,"start":4705,"enrollment":4781,"conditions":4782,"interventions":4783},"NCT03954652","Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - \"GENOME FIRST APPROACH\"",[92],"2022-10-01",1350,[21,35],[4762]]